







Day: Monday Date: 9/23/2002

Time: 08:42:12

Inventor Name Search Result

Your Search was:

Application#	Patent#	Status	Date Filed	Title	Inventor Name
06089293	4302447	150	•	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
06285470	Not Issued	166		PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
<u>06783601</u>	Not Issued	166		COMPOSITIONS OF COPPER AND FATTY ACIDS	HORROBIN, DAVID F.
06798717	Not Issued	166		PHARMACEUTICAL COMPOSITION	HORROBIN, DAVID F
06804247	Not Issued	166			HORROBIN, DAVID F.
07092191	4855136	150		THERAPEUTIC COMPOSITION AND METHOD	HORROBIN, DAVID F.
07353248	Not Issued	166		PHARMACEUTICAL COMPOSITION	HORROBIN, DAVID F.
07361699	Not Issued	166		<u> </u>	HORROBIN , DAVID F.
07363334	Not Issued	166		COMPOSITION AND METHOD FOR TREATMENT OF PEPTIC ULCERS	HORROBIN, DAVID F.
07835072	Not Issued	168		TOPICAL PREPARATIONS CONTAINING TARS AND FATTY ACIDS	HORROBIN, DAVID F.
<u>07818501</u>	5145686	150		TOPICAL PHARMACEUTICAL COMPOSITIONS	HORROBIN, DAVID F.
07611881	Not Issued	166	11/13/1990		HORROBIN, DAVID F.
07598822	Not Issued	161		COMPOSITION AND METHOD FOR TREATMENT OF PEPTIC ULCERS	HORROBIN, DAVID F.
07598782	Not	166	10/18/1990	ESSENTIAL FATTY ACID	HORROBIN,

	Issued			COMPOSITION	DAVID F.
07597091	Not Issued	166	H	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
07593388	Not Issued	161		PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
<u>07591604</u>	5120760	150		TREATING TARDIVE DYSKINESIA WITH ESSENTIAL FATTY ACID COMPOSITIONS	HORROBIN, DAVID F.
07578498	Not Issued	166	09/06/1990	FATTY ACID THERAPY	HORROBIN , DAVID F.
06581671	RE31836	150		PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
06575744	4681896	150		PHARAMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
06559756	Not Issued	161		TOPICAL PHARMACEUTICAL COMPOSITIONS	HORROBIN, DAVID F.
06254113	Not Issued	161	11	TREATMENT OF HEART DISEASE	HORROBIN , DAVID F.
06251901	4328243	150			HORROBIN, DAVID F.
06038938	4287202	150		TREATMENT AND/OR PROPHYLAXIS OF SPASMS OF CORONARY ARTERIES	HORROBIN , DAVID F.
08930670	Not Issued	168	11/06/1997		HORROBIN, DAVID F.
08919148	Not Issued	161		1	HORROBIN , DAVID F.
08500017	Not Issued	161			HORROBIN, DAVID F.
06846093	Not Issued	161			HORROBIN, DAVID F.
06839228	4666701	150			HORROBIN, DAVID F.
06833286	Not Issued	166			HORROBIN, DAVID F.
08491244	Not Issued	166			HORROBIN, DAVID F.
08482446	Not Issued	161	11		HORROBIN, DAVID F.
08285769	Not	166	08/03/1994	PHARMACEUTICAL DIETARY	HORROBIN,

	Issued			COMPOSITION	DAVID F.
08061110	5380757	150	11	METHOD OF TREATING VULVAR DYSTROPHY AND VAGINAL DRYNESS	HORROBIN, DAVID F.
08054344	Not Issued	161		METHODS AND COMPOSITIONS FOR THE TREATMENT OF THE SKIN	HORROBIN , DAVID F.
08051436	5318991	150		FATTY ACID TREATMENT TO REDUCE CALCIUM EXCRETION	HORROBIN, DAVID F.
07847884	Not Issued	166		METHOD OF REDUCING PORPHYRIN TOXICITY USING FATTY ACIDS	HORROBIN , DAVID F.
07841770	Not Issued	161		TREATMENT OF SKIN DISORDERS	HORROBIN, DAVID F.
07363333	Not Issued	161		PHARMACEUTICAL COMPOSITION	HORROBIN , DAVID F.
07359565	4977187	150	11	TREATING SCHIZOPHRENIA WITH ESSENTIAL FATTY ACID COMPOSITIONS	HORROBIN , DAVID F.
07117440	Not Issued	166	11/04/1987		HORROBIN , DAVID F.
07089035	Not Issued	161		TOPICAL PHARMACEUTICAL COMPOSITIONS	HORROBIN, DAVID F.
<u>06798721</u>	Not Issued	166	31		HORROBIN, DAVID F.
06786517	Not Issued	166		TOPICAL PHARMACEUTICAL COMPOSITIONS	HORROBIN, DAVID F.
<u>08930701</u>	<u>5990164</u>	150		AMINE SALTS OF	HORROBIN , DAVID FREDERICK
09147113	Not Issued	041		SCHIZOPHRENIA, USING	HORROBIN, DAVID FREDERICK
09376617	6245811	150		BIOACTIVE COMPOUNDS	HORROBIN, DAVID FREDERICK
06004924	4273763	150		DIETARY COMPOSITIONS	HORROBIN , DAVID FREDERICK
06029058	4309415	150		METHOD AND COMPOSITION FOR TREATING INFLAMMATORY DISORDERS	HORROBIN, DAVID FREDERICK
09155550	Not	041	11/12/1998	POLYETHYLENE GLYCOL	HORROBIN,

http://neo/cgi-bin/expo/InvInfo/invquery.pl?FAM_NAM=HORROBIN&GIV_NAM=DAVID% 9/23/02

	Last Name	First Name	
Search Another: Inventor			
	HORROBIN	DAVID F	Searc

To go back use Back button on your browser toolbar.




Day: Monday Date: 9/23/2002

Time: 08:42:38

Inventor Name Search Result

Your Search was:

Application#	Patent#	Status	Date Filed	Title	Inventor Name
08945667	Not Issued	071	01/28/1998	1,3-PROPANE DIOL DERIVATIVES AS BIOACTIVE COMPOUNDS	HORROBIN, DAVID F
06846093	Not Issued	161		METHODS AND COMPOSITIONS FOR THE TREATMENT OF THE SKIN	HORROBIN, DAVID F.
06846094	Not Issued	161	03/31/1986	ANTI-VIRAL COMPOSITIONS	HORROBIN, DAVID F.
<u>07139071</u>	Not Issued	166	1	PHARMACEUTICAL AND DIETARY COMPOSITIONS	HORROBIN, DAVID F.
07147208	4810497	150	01/22/1988	PHARMACEUTICAL COMPOSITIONS	HORROBIN, DAVID F.
07159128	4886670	250	02/23/1988		HORROBIN, DAVID F.
07163327	Not Issued	166			HORROBIN, DAVID F.
07168603	4888326	250			HORROBIN, DAVID F.
07377817	Not Issued	161			HORROBIN, DAVID F.
07397789	5116871	150			HORROBIN, DAVID F.
07406526	Not Issued	166			HORROBIN, DAVID F.



07670518	Not Issued	166	03/18/1991	TOPICAL PREPARATIONS CONTAINING TARS AND FATTY ACIDS	HORROBIN, DAVID F.
07668700	Not Issued	166	03/07/1991	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
07429601	5080909	150	10/31/1989	ANTI-VIRAL COMPOSITIONS	HORROBIN, DAVID F.
<u>07211057</u>	Not Issued	166	06/24/1988	ESSENTIAL FATTY ACID COMPOSITIONS	HORROBIN, DAVID F.
07182291	Not Issued	161	04/15/1988	LITHIUM SALT-CONTAINING PHARMACEUTICAL COMPOSITIONS	HORROBIN, DAVID F.
06903469	Not Issued	166	09/04/1986	DRUG TREATMENTS	HORROBIN, DAVID F.
09163388	Not Issued	161	09/30/1998	STABILISATION OF POLYUNSATURATES	HORROBIN, DAVID F.
07876908	Not Issued	166	04/30/1992	PHARMACEUTICAL DIETARY COMPOSITION	HORROBIN, DAVID F.
08106989	5618558	150	08/16/1993	FATTY ACID TREATMENT	HORROBIN , DAVID F.
08109482	Not Issued	166	08/20/1993	FATTY ACID TREATMENT	HORROBIN, DAVID F.
08111523	Not Issued	166		METHOD FOR THE SAFE ADMINISTRATION OF FATTY ACID	HORROBIN, DAVID F.
08111524	Not Issued	166	08/25/1993	METHOD FOR THE SAFE ADMINISTRATION OF FATTY ACID	HORROBIN, DAVID F.
08297215	<u>5635189</u>	150	08/29/1994	TOCOPHEROLS	HORROBIN, DAVID F.
08306935	Not Issued	166	II .	METHOD OF PREVENTING OCCLUSION OF ARTERIES	HORROBIN, DAVID F.
08516687	Not Issued	161	08/18/1995	FATTY ACID THERAPY	HORROBIN, DAVID F.
08531108	Not Issued	168	09/20/1995	FATTY ACID TREATMENT	HORROBIN, DAVID F.
<u>08732454</u>	Not Issued	161		TUMOUR LOCALISING PHOTOSENSITISING COMPOUNDS	HORROBIN, DAVID F.
08944407	Not Issued	161		METHOD FOR THE SAFE ADMINSTRATION OF FATTY ACID	HORROBIN, DAVID F.
08945779	Not Issued	161	[]		HORROBIN, DAVID

				FREDERICK
<u>09403754</u>	Not Issued	161		HORROBIN, DAVID FREDERICK

Search Another: Inventor
HORROBIN

First Name

First Name

Search

Search

To go back use Back button on your browser toolbar.



Day: Monday Date: 9/23/2002

Time: 08:43:06

Inventor Name Search Result

Your Search was:

Application#	Patent#	Status	Date Filed	Title	Inventor Name
08365171	5516801	150		FATTY ACID TREATMENT FOR ECTOPIC CALCIUM DEPOSITION	HORROBIN, DAVID F
07892814	Not Issued	166	06/05/1992	FATTY ACID TREATMENT	HORROBIN, DAVID F.
07912017	Not Issued	168		METHODS AND COMPOSITIONS FOR THE TREATMENT OF THE SKIN	HORROBIN, DAVID F.
07912772	Not Issued	166	07/13/1992	PREPARATION OF FATTY ACID MEDICAMENTS	HORROBIN, DAVID F.
<u>08131850</u>	Not Issued	166	10/05/1993	FATTY ACID THERAPY	HORROBIN, DAVID F.
<u>08367819</u>	5580556	150	01/03/1995	PHARMACEUTICAL COMPOSITIONS CONTAINING INTERFERONS AND FATTY ACIDS	HORROBIN, DAVID F.
08555019	Not Issued	166	11/13/1995	FORTIFIED FRUIT JUICE	HORROBIN, DAVID F.
08557545	5859055	150		METHOD OF PREVENTING OCCLUSION OF ARTERIES	HORROBIN, DAVID F.
<u>08796901</u>	6069168	150		COMPOSITIONS FOR TREATMENT OF DIABETIC COMPLICATIONS	HORROBIN, DAVID F.
06682829	Not Issued	161		PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
06669958	Not Issued	166		PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
06653767	Not Issued	166		TOPICAL PREPARATIONS CONTAINING TARS AND FATTY ACIDS	HORROBIN, DAVID F.
06650997	Not Issued	166			HORROBIN, DAVID F.

			U	11	
<u>06647861</u>	Not Issued	166	09/05/1984	PHARMACEUTICAL AND DIETARY COMPOSITIONS	HORROBIN, DAVID F.
06402929	Not Issued	166	07/29/1982	PHARMACEUTICAL AND DIETARY COMPOSITIONS	HORROBIN, DAVID F.
06397350	Not Issued	166	07/12/1982	METHOD FOR ENCHANCEMENT OF 1- SERIES PG PRODUCTION	HORROBIN, DAVID F.
06267657	Not Issued	161	05/27/1981	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
06150402	4388324	150	05/15/1980	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
07704603	5178873	150	05/23/1991	ESSENTIAL FATTY ACID TREATMENT	HORROBIN, DAVID F.
07483992	Not Issued	166	02/22/1990	IRON-CONTAINING COMPOSITIONS AND METHOD FOR TREATING CANCER	HORROBIN, DAVID F.
07480375	4996233	150	02/14/1990	A METHOD OF REDUCING PORPHYRIN TOXICITY USING FATTY ACIDS	HORROBIN, DAVID F.
07253397	Not Issued	166	10/04/1988	FATTY ACID COMPOSITION	HORROBIN, DAVID F.
07243235	Not Issued	166		PHARMACEUTICAL AND DIETARY COMPOSITIONS	HORROBIN, DAVID F.
<u>07240276</u>	Not Issued	161	09/06/1988	TREATMENT OF MALE PATTERN BALDNESS AND OF UNWANTED HAIR GROWTH	HORROBIN, DAVID F.
07236442	Not Issued	161	08/25/1988	NUTRITIONAL SUPPLEMENT	HORROBIN , DAVID F.
07235747	Not Issued	166	08/22/1988	TREATMENT OF SKIN DISORDERS	HORROBIN, DAVID F.
07232515	4898885	250	08/15/1988	PHARMACEUTICA AND DIETARY COMPOSITIONS	HORROBIN, DAVID F.
08155631	Not Issued	161		PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
07963597	5422115	150			HORROBIN, DAVID F.
07959472	5264217	150		METHOD OF INCREASING THE TOTAL FAT CONTENT OF MILK	HORROBIN, DAVID F.
<u>07956460</u>	5324748	250		METHOD FOR ENHANCEMENT OF 1-SERIES	HORROBIN, DAVID F.

				PG PRODUCTION	
07936321	Not Issued	166	08/28/1992	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
07732492	5262174	250	07/18/1991	ANTI-VIRAL COMPOSITIONS	HORROBIN, DAVID F.
07717862	5198468	150	06/19/1991	ESSENTIAL FATTY ACID COMPOSITION	HORROBIN, DAVID F.
07711499	Not Issued	166	05/31/1991	FATTY ACID COMPOSITION	HORROBIN, DAVID F.
07711104	5128152	150	06/03/1991	IRON-CONTAINING COMPOSITIONS AND METHOD FOR TREATING CANCER	HORROBIN, DAVID F.
07217508	Not Issued	166	07/07/1988	TREATMENT OF CEREBRAL DISORDERS	HORROBIN, DAVID F.
06939965	Not Issued	161	12/10/1986	ANTI-VIRAL COMPOSITIONS	HORROBIN, DAVID F.
06928596	Not Issued	166	11/10/1986	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
06925454	Not Issued	166	10/31/1986	PHARMACEUTICAL COMPOSITION	HORROBIN, DAVID F.
06921855	Not Issued	161	10/22/1986	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
06911794	4826877	150		PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
06911719	4758592	150	•	METHOD OF TREATING OR PREVENTING ENDOMETRIOSIS	HORROBIN, DAVID F.
06683328	Not Issued	166	i I	PHARMACEUTICAL COMPOSITION	HORROBIN, DAVID F.
<u>08784105</u>	5888541	150	01/15/1997	FATTY ACID TREATMENT	HORROBIN, DAVID F.
<u>08555746</u>	Not Issued	161	11/09/1995		HORROBIN, DAVID F.
08543799	5866703	150	10/16/1995	TRIGLYCERIDES	HORROBIN , DAVID F.
08136236	Not Issued	161	10/15/1993		HORROBIN , DAVID F.
<u>08136606</u>	Not Issued	166			HORROBIN , DAVID F.
08352460	Not Issued	166	12/09/1994		HORROBIN, DAVID F.

4	
U	

	Last Name	First Name	
Search Another: Inventor	*************************************	· ·	
	HORROBIN	DAVID F	Search

To go back use Back button on your browser toolbar.



Day: Monday Date: 9/23/2002

Time: 08:43:31

1

Inventor Name Search Result

Your Search was:

Application#	Patent#	Status	Date Filed	Title	Inventor Name
<u>08155631</u>	Not Issued	161	11/22/1993	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
08158363	Not Issued	166		PHARMACEUTICAL DIETARY COMPOSITION	HORROBIN, DAVID F.
08158986	5552150	150	11/30/1993	COMPOSITIONS CONTAINING DI- LINOLEOYL-MONO-GAMMA- LINOLENYL-GLYCEROL	HORROBIN, DAVID F.
08178553	5604216	150	01/06/1994	COMPOSITIONS CONTAINING ESTERS OF UNSATURATED FATTY ACIDS	HORROBIN, DAVID F.
08181020	Not Issued	169	01/14/1994	TRIGLYCERIDES	HORROBIN , DAVID F.
08181497	Not Issued	169	01/14/1994	TRIGLYCERIDES	HORROBIN, DAVID F.
08184114	Not Issued	166		INTERNAL RADIATION DAMAGE	HORROBIN , DAVID F.
08372846	Not Issued	166		METHODS OF REDUCING PORPHYRIN TOXICITY USING FATTY ACIDS	HORROBIN , DAVID F.
<u>08378708</u>	5508307	150		METHOD FOR THE SAFE ADMINISTRATION OF FATTY ACID	HORROBIN, DAVID F.
08392628	5603959	150	02/22/1995		HORROBIN, DAVID F.
08405431	Not Issued	161	03/16/1995		HORROBIN, DAVID F.
08584426	5922345	150	01/11/1996		HORROBIN, DAVID F.
08600004	5614208	150			HORROBIN, DAVID F.

				MONO-GAMMA-LINOLENYL GLYCEROL	
08600005	5620701	150	02/14/1996	METHODS OF TREATMENT USING DI-LINOLEOYL- MONO-GAMMA-LINOLENYL GLYCEROL	HORROBIN, DAVID F.
08604444	Not Issued	161	02/21/1996	SCHIZOPHRENIA	HORROBIN, DAVID F.
08611525	5589509	150	03/06/1996	METHODS OF REDUCING PORPHYRIN TOXICITY USING FATTY ACIDS	HORROBIN, DAVID F.
08810458	Not Issued	161	03/04/1997	FORTIFIED FRUIT JUICE	HORROBIN, DAVID F.
07009093	Not Issued	166	01/29/1987	METHOD FOR ENHANCEMENT OF 1-SERIES PG PRODUCTION	HORROBIN, DAVID F.
07008751	Not Issued	166			HORROBIN, DAVID F.
07007109	4753964	150	II .	PHARMACEUTICAL COMPOSITIONS	HORROBIN, DAVID F.
06719953	4738853	150	04/04/1985	FOOD PRODUCTION	HORROBIN, DAVID F.
06700065	Not Issued	166		METHOD FOR ENHANCEMENT OF 1-SERIES PG PRODUCTION	HORROBIN, DAVID F.
06458466	Not Issued	161		TOPICAL PHARMACEUTICAL COMPOSITIONS	HORROBIN, DAVID F.
06450037	Not Issued	166			HORROBIN, DAVID F.
06272083	4415554	150			HORROBIN, DAVID F.
06272081	4444755	150	I !	TREATMENT FOR SKIN DISORDERS	HORROBIN, DAVID F.
08197741	Not Issued	161	11	TREATMENT OF A GROUP OF RELATED DISORDERS	HORROBIN, DAVID F.
08197459	Not Issued	166			HORROBIN, DAVID F.
<u>08187046</u>	Not Issued	166	01/27/1994		HORROBIN, DAVID F.
08187044	Not Issued	166	01/27/1994		HORROBIN, DAVID F.
<u>08187042</u>	<u>5466841</u>	150			HORROBIN, DAVID F.

				UNSATURATED FATTY ACIDS	
07990190	5276020	150	12/14/1992	ANTI-VIRALS	HORROBIN , DAVID F.
07981116	5378732	150	11/25/1992		HORROBIN, DAVID F.
07765008	5223271	150	09/24/1991	LITHIUM TREATMENT	HORROBIN , DAVID F.
07522085	Not Issued	166	† I	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN , DAVID F.
08202981	Not Issued	169	02/28/1994	TREATMENT OF VIRAL INFECTIONS	HORROBIN, DAVIDF.
07521075	5216142	150	04/10/1990		HORROBIN, DAVID F.
07504037	Not Issued	166	04/04/1990	TREATMENT OF CEREBRAL DISORDERS	HORROBIN, DAVID F.
07280410	4970076	150	12/06/1988		HORROBIN, DAVID F.
07274358	Not Issued	166	11/21/1988	1	HORROBIN, DAVID F.
07273680	4965075	150	11/21/1988		HORROBIN, DAVID F.
07045545	4806569	150	05/04/1987		HORROBIN, DAVID F.
07042526	Not Issued	166	04/27/1987	PHARMACEUTICAL COMPOSITION	HORROBIN, DAVID F.
07028272	Not Issued	166	03/20/1987	IRON-CONTAINING COMPOSITION AND METHOD FOR TREATMENT OF CANCER	HORROBIN, DAVID F.
06069493	4248872	150		1	HORROBIN, DAVID F.
09254286	6407075	150	07/06/1999		HORROBIN, DAVID F.
08823790	5763484	250	II i	1	HORROBIN, DAVID F.
08828716	5847000	150	03/28/1997		HORROBIN, DAVID F.
09034029	6177470	150			HORROBIN , DAVID F.

09052003	Not Issued	161	03/31/1998	TRIGLYCERIDES	HORROBIN, DAVID F.	
----------	---------------	-----	------------	---------------	-----------------------	--

First Name **Last Name**

Search Another: Inventor HORROBIN Search DAVID F

To go back use Back button on your browser toolbar.



Day: Monday Date: 9/23/2002

Time: 08:44:08

Inventor Name Search Result

Your Search was:

Application#	Patent#	Status	Date Filed	Title	Inventor Name
08440987	<u>5670540</u>	150	05/15/1995	TRIGLYCERIDES OF FATTY ACIDS	HORROBIN, DAVID F
08202981	Not Issued	169	02/28/1994	TREATMENT OF VIRAL INFECTIONS	HORROBIN, DAVID F.
08206399	Not Issued	163	03/07/1994	FATTY ACID TREATMENT	HORROBIN, DAVID F.
08208465	Not Issued	166	l fi	TREATMENT OF VIRAL INFECTIONS	HORROBIN, DAVID F.
08208481	Not Issued	166	03/08/1994	NUTRITION	HORROBIN, DAVID F.
08214553	5562913	150	03/18/1994	FORMULATION FOR USE IN SMOKERS	HORROBIN, DAVID F.
08628692	5871757	150	10/16/1996	STABILISATION OF POLYUNSATURATES	HORROBIN , DAVID F.
08649292	Not Issued	166	il i	TREATMENT OF VIRAL INFECTIONS	HORROBIN , DAVID F.
06240295	Not Issued	166	03/04/1981	PHARMACEUTICAL COMPOSITIONS	HORROBIN, DAVID F.
06487762	Not Issued	166		PHARMACEUTICAL COMPOSITION	HORROBIN, DAVID F.
<u>06476708</u>	4535093	150		PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
06469445	Not Issued	166		PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
06469444	Not Issued	166		PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
06469443	Not Issued	166	1	PHARMACEUTICAL COMPOSITION	HORROBIN, DAVID F.
06469442	Not Issued	166		PHARMACEUTICAL COMPOSITION	HORROBIN, DAVID F.
06345214	4386072	150	02/03/1982	TREATMENT OF DISORDERS	HORROBIN,

				OF INFLAMMATION AND	DAVID F.
				IMMUNITY AND DISORDERS ASSOCIATED WITH SMOOTH MUSCLE SPASM AND COMPOSITIONS THEREOF	
06345204	Not Issued	161	02/03/1982	TOPICAL PHARMACEUTICAL COMPOSITIONS	HORROBIN, DAVID F.
06277671	Not Issued	161	06/26/1981	TREATMENT OF DISORDERS OF INFLAMMATION AND IMMUNITY AND DISORDERS ASSOCIATED WITH SMOOTH MUSCLE SPASM	HORROBIN, DAVID F.
07561722	Not Issued	161		SKIN IMPROVING COMPOSTITION AND METHOD	HORROBIN, DAVID F.
07560005	Not Issued	166	07/27/1990	METHODS AND COMPOSITIONS FOR THE TREATMENT OF THE SKIN	HORROBIN, DAVID F.
07550670	Not Issued	161	07/10/1990	PHARMACEUTICAL AND DIETARY USES OF FATTY ACIDS	HORROBIN, DAVID F.
07536991	Not Issued	166		TREATMENT OF SKIN DISORDERS	HORROBIN, DAVID F.
07331023	Not Issued	166	03/28/1989	METHOD FOR ENHANCEMENT OF 1-SERIES PG PRODUCTION	HORROBIN , DAVID F.
07329881	5252333	150		LITHIUM SALT-CONTAINING PHARMACEUTICAL COMPOSITIONS	HORROBIN, DAVID F.
07329277	Not Issued	166	03/27/1989	NUTRITIONAL SUPPLEMENT	HORROBIN, DAVID F.
07321204	4997657	150	11	SKIN IMPROVING COMPOSITION AND METHOD	HORROBIN, DAVID F.
07312730	Not Issued	166	1	TOPICAL PHARMACEUTICAL COMPOSITIONS	HORROBIN, DAVID F.
08013163	Not Issued	166	11	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
08002545	Not Issued	166	01/11/1993	FATTY ACID COMPOSITION	HORROBIN, DAVID F.
07810434	Not Issued	166	1	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
07803913	Not Issued	166	11		HORROBIN, DAVID F.
07802644	Not	166	12/09/1991	NUTRITION	HORROBIN,

	Issued				DAVID F.
07790075	Not Issued	166	11/12/1991	FATTY ACID THERAPY	HORROBIN, DAVID F.
07771800	Not Issued	166	10/07/1991	METHODS AND COMPOSITIONS FOR THE TREATMENT OF THE SKIN	HORROBIN, DAVID F.
07571012	Not Issued	166	08/22/1990	FATTY ACID COMPOSITION	HORROBIN, DAVID F.
07561992	Not Issued	166	08/02/1990	PHARMACEUTICAL COMPOSITIONS	HORROBIN, DAVID F.
07307952	4868212	150	02/09/1989	PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
07307945	Not Issued	166		PHARMACEUTICAL AND DIETARY COMPOSITION	HORROBIN, DAVID F.
07082914	Not Issued	161	08/10/1987	PHARMACEUTICAL COMPOSITION	HORROBIN , DAVID F.
07060857	Not Issued	161	06/12/1987	ANTI-VIRAL COMPOSITIONS	HORROBIN, DAVID F.
06776982	Not Issued	166	09/12/1985	PHARMACEUTICAL COMPOSITION	HORROBIN, DAVID F.
06772192	Not Issued	166	09/03/1985	PHARMACEUTICAL COMPOSITIONS	HORROBIN , DAVID F.
06763411	Not Issued	166	H	TREATMENT OF SKINDISORDERS	HORROBIN, DAVID F.
06743394	Not Issued	161	06/11/1985	ANTI-VIRAL COMPOSITIONS	HORROBIN , DAVID F.
06240294	Not Issued	161		PHARMACEUTICAL AND DIETARY COMPOSITIONS	HORROBIN , DAVID F.
08215963	Not Issued	168	03/18/1994	PREPARATION OF FATTY ACID MEDICAMENTS	HORROBIN, DAVID F.
08408135	5583159	150		TREATMENT OF INTERNAL RADIATION DAMAGE	HORROBIN, DAVID F.
08416529	Not Issued	166		METHOD FOR THE SAFE ADMINISTRACTION OF FATTY ACID	HORROBIN, DAVID F.
08416930	Not Issued	168	{	PHARMACEUTICAL DIETARY COMPOSITION	HORROBIN, DAVID F.
08422614	5594031	150		METHODS AND COMPOSITIONS FOR THE TREATMENT OF THE SKIN	HORROBIN, DAVID F.

Last Name

First Name

Search Another: Inventor	HORROBIN	DAVID F	Search

To go back use Back button on your browser toolbar.



Day: Monday Date: 9/23/2002

Time: 08:44:22

Inventor Name Search Result

Your Search was:

Last Name = HORROBIN First Name = DAVID F

Application#	Patent#	Status	Date Filed	Title	Inventor Name
08013163	Not Issued	166			HORROBIN, DAVID F.
08015035	Not Issued	166		PHARMACEUTICAL COMPOSITIONS	HORROBIN, DAVID F.
08462557	Not Issued	161	06/05/1995		HORROBIN, DAVID F.
09093775	Not Issued	168			HORROBIN, DAVID F.

Inventor Search Completed: No Records to Display.

Search Another: Inventor
HORROBIN
First Name
First Name

Search
Search

To go back use Back button on your browser toolbar.



Day: Monday Date: 9/23/2002

Time: 08:44:48

Inventor Name Search Result

Your Search was:

Last Name = MANKU First Name = MEHAR

Application#	Patent#	Status	Date Filed	Title	Inventor Name
09376617	6245811	150		FATTY ACID ESTERS AS BIOACTIVE COMPOUNDS	MANKU, MEHAR
08945667	Not Issued	071		1,3-PROPANE DIOL DERIVATIVES AS BIOACTIVE COMPOUNDS	MANKU, MEHAR
08945779	Not Issued	161	01/26/1998	FATTY ACIDS ESTERS AS BIOACTIVE COMPOUNDS	MANKU, MEHAR
08952305	6015821	150		NICOTINIC ACID ESTERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM	MANKU, MEHAR
08440987	5670540	150	05/15/1995	TRIGLYCERIDES OF FATTY ACIDS	MANKU, MEHAR S
06783601	Not Issued	166		COMPOSITIONS OF COPPER AND FATTY ACIDS	MANKU, MEHAR S.
06839228	4666701	150		PHARMACEUTICAL AND DIETARY COMPOSITIONS	MANKU , MEHAR S.
08543799	5866703	150	10/16/1995	TRIGLYCERIDES	MANKU , MEHAR S.
08828716	5847000	150	03/28/1997	FATTY ACID DERIVATIVES	MANKU, MEHAR S.
07273680	4965075	150	11/21/1988	METHOD OF INCREASING 1- SERIES PGS IN THE BODY	MANKU, MEHAR S.
08187046	Not Issued	166	01/27/1994	TRIGLYCERIDES	MANKU, MEHAR S.
08187044	Not Issued	166	01/27/1994	TRIGLYCERIDES	MANKU, MEHAR S.
08187042	5466841	150		FORMULATIONS CONTAINING UNSATURATED FATTY ACIDS	
08388667	Not Issued	166	02/17/1995	FATTY ACID DERIVATIVES	MANKU, MEHAR S.

<u>08930670</u>	Not Issued	168	11/06/1997	TRIGLYCERIDES	MANKU, MEHAR S.
08297215	5635189	150	08/29/1994	TOCOPHEROLS	MANKU, MEHAR S.
09155550	Not Issued	041	11/12/1998	POLYETHYLENE GLYCOL ESTERS OF POLYUNSATURATED FATTY ACIDS	MANKU, MEHAR SINGH
09052003	Not Issued	161	03/31/1998		MANKU, MEHAR SINGH
09034029	6177470	150		METHODS OF TREATMENT USING ASCORBYL GAMMA LINOLENIC ACID OR ASCORBYL DIHOMO-GAMMA- LINOLENIC ACID	MANKU, MEHAR S.
09424194	Not Issued	161		GLUCOSAMINE FATTY ACID COMPOSITIONS AND THEIR USE	MANKU, MEHAR SINGH

Inventor Search Completed: No Records to Display.

	Last Name	First Name	
Search Another: Inventor		A ELIA D	Search
	MANKU	MEHAR	Geardi

To go back use Back button on your browser toolbar.



Day: Monday Date: 9/23/2002

Time: 08:45:15

Inventor Name Search Result

Your Search was:

Last Name = PITT

First Name = ANDREA

	<u> </u>				
Application#	Patent#	Status	Date Filed	Title	Inventor Name
09376617	6245811	150	08/18/1999	FATTY ACID ESTERS AS BIOACTIVE COMPOUNDS	PITT, ANDREA
08945667	Not Issued	071		1,3-PROPANE DIOL DERIVATIVES AS BIOACTIVE COMPOUNDS	PITT, ANDREA
08945779	Not Issued	161	01/26/1998	FATTY ACIDS ESTERS AS BIOACTIVE COMPOUNDS	PITT, ANDREA
08952305	6015821	150	03/03/1998	NICOTINIC ACID ESTERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM	PITT, ANDREA
<u>06789326</u>	4697798	150	10/21/1985	APPARATUS FOR LIFTING EQUIPMENT	PITTER, ANDREAS
06586604	Not Issued	161		PROCEDURE FOR OPTIMIZING THE REGULATION OF ELECTRODES IN AN ARC FURNACE, AND DEVICE WHICH CARRIES OUT THE PROCEDURE	PITTINI, ANDREA
06587726	4644559	250		PROCEDURE FOR CONTROLLING THE TYPE OF ARC IN AN ELECTRICAL FURNACE, AND ARC FURNACE WHICH EMPLOYS THE PROCEDURE	PITTINI, ANDREA
06206699	Not Issued	161		COOLING PANEL FOR ELECTRIC ARC FURNACES	PITTINI, ANDREA

Inventor Search Completed: No Records to Display.

Search Another: Inventor

Last Name

First Name

PITT

ANDREA

Search

To go back use Back button on your browser toolbar.



Day: Monday Date: 9/23/2002

Time: 08:46:38

Inventor Name Search Result

Your Search was:

Last Name = BRADLEY

First Name = PAUL

Application#	Patent#	Status	Date Filed	Title	Inventor Name
08945667	Not Issued	071		1,3-PROPANE DIOL DERIVATIVES AS BIOACTIVE COMPOUNDS	BRADLEY, PAUL
07658395	Not Issued	161		PHOTOLITHOGRAPHIC PATTERNING OF THIN FILMS	BRADLEY, PAUL
07666397	D326261	150	03/08/1991	TRACKBALL FOR COMPUTER	BRADLEY, PAUL
07665840	D342241	150	03/08/1991	COMPUTER TRACKBALL	BRADLEY, PAUL
07159039	4972042	150		BLOCKING ARRANGEMENT FOR SUPPRESSING FLUID TRANSMISSION IN CABLES	BRADLEY, PAUL A.
07445541	Not Issued	161	1	PACKET FILTER FOR BRIDGE BETWEEN NETWORKS	BRADLEY, PAUL A.
<u>09380375</u>	6201004	150		DIOXINO DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS	BRADLEY, PAUL ANTHONY
08110389	5400026	150		FLASH ANALOG-TO-DIGITAL CONVERTER EMPLOYING JOSEPHSON JUNCTIONS	BRADLEY, PAUL D.
07658396	Not Issued	164		NON DESTRUCTIVE READ- OUT MEMORY CELL AND MEMORY ARRAY WITH A SENSE JOSEPHSON JUNCTION	BRADLEY, PAUL D.
<u>07658404</u>	Not Issued	161		MEMORY EMPLOYING JOSEPHSON JUNCTIONS	BRADLEY, PAUL D.
09193809	<u>5951141</u>	150		HEAD MOUNTED ILLUMINATION DEVICE	BRADLEY, PAUL DAVID
07091783	D302426	150	09/01/1987	COMPUTER MOUSE	BRADLEY, PAUL E.
08925831	6005553	150	09/05/1997	ERGONOMIC COMPUTER	BRADLEY, PAUL

		į		MOUSE	E.
08129811	5438475	150		PORTABLE COMPUTER WITH AN ELECTRONIC PEN STORAGE TURRET	BRADLEY, PAUL E.
09352668	Not Issued	120		ERGONOMIC COMPUTER MOUSE MAT	BRADLEY, PAUL E.
60086410	Not Issued	159	05/22/1998	SCALABLE SYSTEM FOR CLUSTERING OF LARGE DATABASES HAVING MIXED DATA ATTRIBUTES	BRADLEY, PAUL S.
06025281	4239308	150	03/29/1979	DISPLAY TRAY ASSEMBLY	BRADLEY, PAUL W.
09841234	Not Issued	094	II I	CONTROLLED EFFECTIVE COUPLING COEFFICIENTS FOR FILM BULK ACOUSTIC RESONATORS	BRADLEY, PAUL
09906581	Not Issued	041		THIN FILM BULK ACOUSTIC RESONATOR (FBAR) AND INDUCTOR ON A MONOLITHIC SUBSTRATE AND METHOD OF FABRICATING THE SAME	BRADLEY, PAUL
60301917	Not Issued	020	06/29/2001	INTERFACE FOR GENERATING AND PRESENTING ITEM RECOMMENDATIONS	BRADLEY, PAUL
<u>29134965</u>	D452226	150	01/03/2001	DIGITAL AUDIO PLAYER	BRADLEY, PAUL
09702499	Not Issued	061	10/31/2000	PACKAGING METHODOLOGY FOR DUPLEXERS USING FBARS	BRADLEY, PAUL
29148377	Not Issued	095	09/19/2001	MP3 AUDIO PLAYER	BRADLEY, PAUL
29134957	D458241	150		DIGITAL AUDIO PLAYER CHARGING STATION	BRADLEY, PAUL
<u>09733704</u>	Not Issued	093		MOUNTING FILM BULK ACOUSTIC RESONATORS IN MICROWAVE PACKAGES USING FLIP CHIP BONDING TECHNOLOGY	BRADLEY, PAUL
<u>29135779</u>	Not Issued	093	II I	MOVEABLE CABINET WITH COMPUTER DISPLAY	BRADLEY, PAUL
10044613	Not Issued	030		REMOVABLE CUSTOMIZABLE INSERTS AND FACEPLATE FOR	BRADLEY, PAUL

				•	
				ELECTRONIC DEVICES	
09798496	Not Issued	030		METHOD OF FABRICATING THIN FILM BULK ACOUSTIC RESONATOR (FBAR) AND FBAR STRUCTURE EMBODYING THE METHOD	BRADLEY, PAUL
09783773	6462631	150	02/14/2001	PASSBAND FILTER HAVING AN ASYMMETRICAL FILTER RESPONSE	BRADLEY, PAUL
09748153	6353002	150	12/27/2000	THERAPEUTIC AGENTS	BRADLEY, PAUL ANTHONY
09746525	6424237	150		BULK ACOUSTIC RESONATOR PERIMETER REFLECTION SYSTEM	BRADLEY, PAUL D.
09799149	Not Issued	094		METHOD OF PROVIDING DIFFERENTIAL FREQUENCY ADJUSTS IN A THIN FILM BULK ACOUSTIC RESONATOR (FBAR) FILTER AND APPARATUS EMBODYING THE METHOD	BRADLEY, PAUL D.
10209579	Not Issued	020		RESONATOR WITH PROTECTIVE LAYER	BRADLEY, PAUL D.
10209602	Not Issued	020		ELECTROSTATIC DISCHARGE PROTECTION ON THIN-FILM RESONATORS	BRADLEY, PAUL D.
10209624	Not Issued	020	07/30/2002	RESONATOR WITH SEED LAYER	BRADLEY, PAUL D.
09799148	Not Issued	041			BRADLEY, PAUL D.
09799153	Not Issued	061		METHOD OF PROVIDING DIFFERENTIAL FREQUENCY ADJUSTS IN A THIN FILM BULK ACOUSTIC RESONATOR (FBAR) FILTER AND APPARATUS EMBODYING THE METHOD	BRADLEY, PAUL D.
<u>09799202</u>	Not Issued	030			BRADLEY, PAUL D.

				THE SAME SUBSTRATE BY SUBTRACTING METHOD AND APPARATUS EMBODYING THE METHOD	
09799204	Not Issued	095		METHOD OF MASS LOADING OF THIN FILM BULK ACOUSTIC RESONATORS (FBAR) FOR CREATING RESONATORS OF DIFFERENT FREQUENCIES AND APPARATUS EMBODYING THE METHOD	BRADLEY, PAUL D.
09799205	Not Issued	041		METHOD FOR PRODUCING THIN FILM BULK ACOUSTIC RESONATORS (FBARS) WITH DIFFERENT FREQUENCIES ON THE SAME SUBSTRATE BY SUBTRACTING METHOD AND APPARATUS EMBODYING THE METHOD	BRADLEY, PAUL D.
29126514	D451916	150	07/13/2000	FACE OF TERMINAL APPARATUS	BRADLEY, PAUL EUGENE
09462697	6436323	150	02/09/2000	PRODUCTION OF FIBRE	BRADLEY, PAUL JONATHAN
<u>09607365</u>	6449612	150		VARYING CLUSTER NUMBER IN A SCALABLE CLUSTERING SYSTEM FOR USE WITH LARGE DATABASES	II - I
09500172	Not Issued	093		ITERATIVE VALIDATION AND SAMPLING-BASED CLUSTERING USING ERROR-TOLERANT FREQUENT ITEM SETS	BRADLEY, PAUL S.
09500265	Not Issued	041		RETROFITTING RECOMMENDER SYSTEMS	BRADLEY, PAUL S.
09845151	Not Issued	030		APPARATUS AND ACCOMPANYING METHODS FOR VISUALIZING CLUSTERS OF DATA AND HIERARCHICAL CLUSTER CLASSIFICATIONS	BRADLEY, PAUL S.
09700606	Not Issued	030		SCALABLE SYSTEM FOR CLUSTERING OF LARGE DATABASES HAVING MIXED DATA ATTRIBUTES	BRADLEY, PAUL S.
09876321	Not Issued	030			BRADLEY, PAUL S.

			OF ATTRIBUTES USED TO CHARACTERIZE A SPARSE DATA SET	
09886771	Not Issued	019	CLUSTERING OF DATABASES HAVING MIXED DATA ATTRIBUTES	BRADLEY, PAUL S.
09500173	Not Issued	030	DATA CLUSTERING USING ERROR-TOLERANT FREQUENT ITEM SETS	BRADLEY, PAUL S.

	Last Name	First Name	
Search Another: Inventor		·	
	BRADLEY	PAUL	Search

To go back use Back button on your browser toolbar.



Day: Monday Date: 9/23/2002

Time: 08:46:52

Inventor Name Search Result

Your Search was:

Last Name = BRADLEY

First Name = PAUL

Application#	Patent#	Status	Date Filed	Title	Inventor Name
<u>07718151</u>	D348057	150	06/13/1991	COMPUTER MOUSE	BRADLEY, PAUL
07731626	5281958	150		POINTING DEVICE WITH ADJUSTABLE CLAMP ATTACHABLE TO A KEYBOARD	BRADLEY, PAUL
29002935	D347628	150	12/23/1992	COMPUTER TRACKBALL	BRADLEY, PAUL
08176428	Not Issued	161		POINTING DEVICE WITH ADJUSTABLE CLAMP ATTACHABLE TO A KEYBOARD	BRADLEY, PAUL
29002937	D353370	150	03/05/1993	COMPUTER TRACKBALL	BRADLEY, PAUL
07528173	Not Issued	164		RETRACTABLE ELECTRICAL EXTENSION CABLE	BRADLEY, PAUL
09282082	6215375	150		BULK ACOUSTIC WAVE RESONATOR WITH IMPROVED LATERAL MODE SUPPRESSION	BRADLEY, PAUL
29071913	D395894	150	05/30/1997	MICROPHONE	BRADLEY, PAUL
29071912	D395893	150	05/30/1997	MICROPHONE	BRADLEY, PAUL
07280997	D311737	150	l i	REMOVABLE HARD DISK DRIVE MODULE	BRADLEY, PAUL
08564155	5741800	150		AZOLYL-CYCLIC AMINE DERIVATES WITH IMMUNOMODULATORY ACTIVITY	BRADLEY, PAUL A.
08809354	Not Issued	161	03/14/1997	SEALING MEMBER	BRADLEY, PAUL A.
09091129	6107310	150	06/16/1998	HETEROARYLCARBOXAMIDE	BRADLEY,

		1		11	ıı i
		_	II I	DERIVATIVES FOR TREATING CNS DISORDERS	PAUL ANTHONY
09331064	6218405	150		HETEROARYLSULFONAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM	BRADLEY, PAUL ANTHONY
09324618	6262637	150		DUPLEXER INCORPORATING THIN-FILM BULK ACOUSTIC RESONATORS (FBARS)	BRADLEY, PAUL D.
29052173	D386756	150	03/25/1996	COMPUTER KEYBOARD	BRADLEY, PAUL E
08129811	5438475	150		PORTABLE COMPUTER WITH AN ELECTRONIC PEN STORAGE TURRET	BRADLEY, PAUL E.
29011532	D355901	150	08/06/1993	COMPUTER MOUSE	BRADLEY, PAUL E.
29087267	D422262	150		HOUSING FOR PIGGYBACK MOUNTED BATTERY FOR PORTABLE PHONE	BRADLEY, PAUL E.
<u>29087266</u>	D413857	150		HOUSING FOR PIGGYBACK MOUNTED BATTERY FOR PORTABLE PHONE	BRADLEY, PAUL E.
29072206	D399835	150		ERGONOMIC COMPUTER MOUSE	BRADLEY, PAUL E.
<u>29056351</u>	D382265	150	06/27/1996	SPEAKERPHONE	BRADLEY, PAUL E.
<u>29021001</u>	D362249	150	03/08/1994	PORTABLE TELEPHONE	BRADLEY, PAUL E.
<u>29011371</u>	Not Issued	169	07/29/1993	PORTABLE TELEPHONE	BRADLEY, PAUL E.
08129835	Not Issued	161	11	PORTABLE COMPUTER DISPLAY MOUNTING APPARATUS	BRADLEY, PAUL E.
08153254	Not Issued	161	11	PORTABLE COMPUTER DISPLAY MOUNTING DEVICE	BRADLEY, PAUL E.
60163557	Not Issued	159	11/05/1999	CAMERA	BRADLEY, PAUL EUGEN
60163555	Not Issued	159		STRAP FOR CAMERA AND LENS- FITTED PHOTO FILM UNIT	BRADLEY, PAUL EUGENE
60163562	Not Issued	159		OBJECT BRIGHTNESS INDICATOR	BRADLEY, PAUL EUGENE
60163556	Not Issued	159		WRAPPING CASE FOR LENS- FITTED PHOTO FILM UNIT	BRADLEY, PAUL EUGENE
29111091	D433679	150	09/22/1999	TERMINAL APPARATUS	BRADLEY,

					PAUL EUGENE
07520289	5042405	150		YARN CONTROL METHOD AND APPARATUS	BRADLEY, PAUL J.
08642490	5782256	250	05/03/1996	CONTOURED FOOT FOR AMBULATORY AID	BRADLEY, PAUL M.
09034834	6115708	150		METHOD FOR REFINING THE INITIAL CONDITIONS FOR CLUSTERING WITH APPLICATIONS TO SMALL AND LARGE DATABASE CLUSTERING	BRADLEY, PAUL S.
09083906	6263337	150		A SCALABLE SYSTEM FOR EXPECTATION MAXIMIZATION CLUSTERING OF LARGE DATABASES	BRADLEY, PAUL S.
09034959	Not Issued	169		METHOD FOR REFINING THE INITIAL CONDITIONS FOR CLUSTERING WITH APPLICATIONS TO SMALL AND LARGE DATABASE CLUSTERING	BRADLEY, PAUL S.
09040219	6374251	150		SCALABLE SYSTEM FOR CLUSTERING OF LARGE DATABASES	BRADLEY, PAUL S.
09042540	6012058	150		SCALABLE SYSTEM FOR K- MEANS CLUSTERING OF LARGE DATABASES	BRADLEY, PAUL S.

Inventor Search Completed: No Records to Display.

	Last Name	First Name	
Search Another: Inventor	BRADLEY	PAUL	Search

To go back use Back button on your browser toolbar.



Day : Monday Date: 9/23/2002

Time: 08:47:08

Inventor Name Search Result

Your Search was:

Last Name = WAKEFIELD

First Name = PAUL

Application#	Patent#	Status	Date Filed	Title	Inventor Name
08945667	Not Issued	071	01/28/1998	1,3-PROPANE DIOL DERIVATIVES AS BIOACTIVE COMPOUNDS	WAKEFIELD, PAUL
<u>08109830</u>	5535261	150		1	WAKEFIELD, PAUL A. J.
08226665	5485507	150	04/12/1994		WAKEFIELD, PAUL A. J.
<u>09155550</u>	Not Issued	041		POLYETHYLENE GLYCOL ESTERS OF POLYUNSATURATED FATTY ACIDS	WAKEFIELD, PAUL ANDREW
09027576	Not Issued	161	02/23/1998	1	WAKEFIELD, PAUL DAVID

Inventor Search Completed: No Records to Display.

Search Another: Inventor WAKEFIELD FAUL First Name

Search Another: Inventor

To go back use Back button on your browser toolbar.



Day: Monday Date: 9/23/2002

Time: 08:44:54

Inventor Name Search Result

Your Search was:

Last Name = MCMORDIE

First Name = AUSTIN

Application#	Patent#	Status	Date Filed	Title	Inventor Name	
08930670	Not Issued	168	11/06/1997	TRIGLYCERIDES	MCMORDIE, AUSTIN	
09376617	6245811	150	08/18/1999	FATTY ACID ESTERS AS BIOACTIVE COMPOUNDS	MCMORDIE , AUSTIN	
08945667	Not Issued	071		1,3-PROPANE DIOL DERIVATIVES AS BIOACTIVE COMPOUNDS	MCMORDIE, AUSTIN	
08952305	6015821	150		NICOTINIC ACID ESTERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM	MCMORDIE, AUSTIN	
09052003	Not Issued	161	03/31/1998	TRIGLYCERIDES	MCMORDIE, AUSTIN	
08187044	Not Issued	166	01/27/1994	TRIGLYCERIDES	MCMORDIE, AUSTIN	
08440987	5670540	150	05/15/1995	TRIGLYCERIDES OF FATTY ACIDS	MCMORDIE, AUSTIN	
08187046	Not Issued	166	01/27/1994	TRIGLYCERIDES	MCMORDIE, AUSTIN	
08187042	5466841	150	01/27/1994	FORMULATIONS CONTAINING UNSATURATED FATTY ACIDS	MCMORDIE, AUSTIN	
08543799	5866703	150	10/16/1995	TRIGLYCERIDES	MCMORDIE, AUSTIN	
08945779	Not Issued	161	01/26/1998	FATTY ACIDS ESTERS AS BIOACTIVE COMPOUNDS	MCMORDIE, AUSTIN	
09424194	Not Issued	161		GLUCOSAMINE FATTY ACID COMPOSITIONS AND THEIR USE		

Inventor Search Completed: No Records to Display.

4	

Last Name

First Name

Search Another: Inventor MCMORDIE

AUSTIN

Search

To go back use Back button on your browser toolbar.



PALM INTRANET

Day: Monday Date: 9/23/2002

Time: 08:44:57

Inventor Name Search Result

Your Search was:

Last Name = KNOWLES First Name = PHILIP

Application#	Patent#	Status	Date Filed	Title	Inventor Name
08930701	5990164	150	03/17/1998	N-ALKYLPOLYHYDROXY AMINE SALTS OF POLYUNSATURATED FATTY ACIDS	KNOWLES, PHILIP
09155550	Not Issued	041		POLYETHYLENE GLYCOL ESTERS OF POLYUNSATURATED FATTY ACIDS	KNOWLES, PHILIP
09376617	6245811	150	08/18/1999		KNOWLES, PHILIP
06044511	4442115	150			KNOWLES, PHILIP
06587969	Not Issued	166	03/09/1984	AMINOETHENES	KNOWLES, PHILIP
08945667	Not Issued	071		1,3-PROPANE DIOL DERIVATIVES AS BIOACTIVE COMPOUNDS	KNOWLES, PHILIP
08945779	Not Issued	161	i	FATTY ACIDS ESTERS AS BIOACTIVE COMPOUNDS	KNOWLES, PHILIP
08952305	6015821	150		NICOTINIC ACID ESTERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM	KNOWLES, PHILIP
08543799	5866703	150	10/16/1995	TRIGLYCERIDES	KNOWLES , PHILIP
08181020	Not Issued	169	01/14/1994	TRIGLYCERIDES	KNOWLES, PHILIP
08388667	Not Issued	166	02/17/1995		KNOWLES, PHILIP
08392628	5603959	150	02/22/1995		KNOWLES, PHILIP

08828716	<u>5847000</u>	150	03/28/1997	FATTY ACID DERIVATIVES	KNOWLES, PHILIP
09034029	6177470	150		METHODS OF TREATMENT USING ASCORBYL GAMMA LINOLENIC ACID OR ASCORBYL DIHOMO-GAMMA- LINOLENIC ACID	KNOWLES, PHILIP
09052003	Not Issued	161	03/31/1998	TRIGLYCERIDES	KNOWLES, PHILIP
06198490	Not Issued	161	10/20/1982	BENZAMIDE DERIVATIVES	KNOWLES, PHILIP
06707528	Not Issued	166	03/04/1985	AMINOETHENES	KNOWLES, PHILIP
08187044	Not Issued	166	01/27/1994	TRIGLYCERIDES	KNOWLES, PHILIP
08187046	Not Issued	166	01/27/1994	TRIGLYCERIDES	KNOWLES, PHILIP
08440987	5670540	150	05/15/1995	TRIGLYCERIDES OF FATTY ACIDS	KNOWLES, PHILIP
06777866	4647569	150	09/19/1985	ANTIARTHRITIC PYRIDYLAMINDETHENE DISULFONYL COMPOUNDS AND USE	KNOWLES, PHILIP

Inventor Search Completed: No Records to Display.

	Last Name	First Name	
Search Another: Inventor			Canada
	KNOWLES	PHILIP	Sealul

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page



PALM INTRANET

Day: Monday Date: 9/23/2002

Time: 08:45:10

Inventor Name Search Result

Your Search was:

Last Name = REDDEN First Name = PETER

Application#	Patent#	Status	Date Filed	Title	Inventor Name
09376617	6245811	150	ì	FATTY ACID ESTERS AS BIOACTIVE COMPOUNDS	REDDEN, PETER
08945667	Not Issued	071		1,3-PROPANE DIOL DERIVATIVES AS BIOACTIVE COMPOUNDS	REDDEN, PETER
08945779	Not Issued	161		FATTY ACIDS ESTERS AS BIOACTIVE COMPOUNDS	REDDEN, PETER
08952305	6015821	150		NICOTINIC ACID ESTERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM	REDDEN, PETER
07036244	Not Issued	161		INFLATABLE SPORTS LUGGAGE BAG	REDDEN, PETER
60270198	Not Issued	020		DIBENZO[C]CHROMEN-6-ONE DERIVATIVES AS ANTI- CANCER AGENTS	REDDEN, PETER
09934086	Not Issued	041		DIBENZO[C]CHROMEN-6-ONE DERIVATIVES AS ANTI- CANCER AGENTS	REDDEN, PETER

Inventor Search Completed: No Records to Display.

	Last Name	First Name	
Search Another: Inventor	DENDENI	DETED	Search
	KEDDEN	PEIER	

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

Welcome to STN International! Enter x:x

LOGINID:ssspta1600rxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
Welcome to STN International
NEWS 1
                Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
        Jun 03 New e-mail delivery for search results now available
NEWS 9
         Jun 10 MEDLINE Reload
NEWS 10
         Jun 10 PCTFULL has been reloaded
NEWS 11
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
         Jul 22 USAN to be reloaded July 28, 2002;
NEWS 13
                saved answer sets no longer valid
         Jul 29 Enhanced polymer searching in REGISTRY
NEWS 14
        Jul 30 NETFIRST to be removed from STN
NEWS 15
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
                now available on STN
                IFIPAT, IFICDB, and IFIUDB have been reloaded
       Aug 19
NEWS 20
NEWS 21
       Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
                Sequence searching in REGISTRY enhanced
NEWS 22 Aug 26
        Sep 03 JAPIO has been reloaded and enhanced
NEWS 23
        Sep 16 Experimental properties added to the REGISTRY file
NEWS 24
NEWS 25
        Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA
             February 1 CURRENT WINDOWS VERSION IS V6.0d,
NEWS EXPRESS
             CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
             AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
             STN Operating Hours Plus Help Desk Availability
NEWS HOURS
NEWS INTER
             General Internet Information
NEWS LOGIN
             Welcome Banner and News Items
NEWS PHONE
             Direct Dial and Telecommunication Network Access to STN
             CAS World Wide Web Site (general information)
NEWS WWW
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 07:48:37 ON 23 SEP 2002

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

0.21

0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 07:48:44 ON 23 SEP 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 SEP 2002 HIGHEST RN 453593-49-2 DICTIONARY FILE UPDATES: 20 SEP 2002 HIGHEST RN 453593-49-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details: http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> s adrenic acid

1 ADRENIC 5576167 ACID

7845 ACIDS 5581876 ACID

(ACID OR ACIDS)

1 ADRENIC ACID L1

(ADRENIC (W) ACID)

=> d

08945667 Page 3 09/23/2002

L1 ANSVER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
RN 2091-25-0 REGISTRY
CN 7,10,13,16-Docosatetraenoic acid (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN Advance acid
FS 3D CONCORD
MF C22 H36 O2
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CSCHEM, DDFU, DRUGU, EMBASE,
MEDLINE, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

PAGE 1-A

HO2C-(CH2)5-CH=CH-CH2-CH=CH-CH2-CH=CH-CH2-CH=CH-

PAGE 1-B

— (CH₂)₄-Me

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

159 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

159 REFERENCES IN FILE CAPLUS (1962 TO DATE)
11 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

08945667 Page 4 09/23/2002

=> s parinaric acid

10 PARINARIC

5576167 ACID 7845 ACIDS

5581876 ACID

(ACID OR ACIDS)

L2 9 PARINARIC ACID

(PARINARIC(W)ACID)

=> d scan

08945667 Page 5 09/23/2002

12 9 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 9,11,13,15-Octadecatetraenoic acid, methyl ester, (2,2,E,E)- (8CI, 9CI)
MF C19 H30 O2

Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):8

L2 9 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 9,11,13,15-Octadecatetraenoic acid, (9E,11E,13E,15E) - (9CI)
MF C10 H28 O2
CI COM

Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 9 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 9,11,13,15-Octadecatetraenoic acid, (92,11E,13E,15Z)- (9CI)
MF C18 H28 OZ
CI COM

Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 9 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cholest-5-en-3-ol (3.beta.)-, 9,11,13,15-octadecatetraenoate (9CI)
MF C45 H72 O2

Absolute stereochemistry. Double bond geometry unknown.



PAGE 1-B

— (CH2) 3 CHMe2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

08945667 Page 6 09/23/2002

L2 9 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 9,11,13,15-Octadecatetraenoic acid (7CI, 8CI, 9CI)
MF C18 H28 O2
CI COM

HO₂C- (CH₂) 7-CH=CH-CH=CH-CH=CH-CH=Et

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 9 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 9,11,13,15-Octadecatetraenoic acid, methyl ester (7CI, 8CI, 9CI)
MF C19 H30 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 9 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 9,11,13,15-Octadecatetraenoic acid, anhydride (9CI)
MF C36 H54 O3

PAGE 1-A

O O

|| ||
||
Et-CH=CH-CH=CH-CH=CH-(CH₂)₇-C-O-C-(CH₂)₇-CH=


PAGE 1-B

= CH- CH= CH- CH= CH- CH= CH- Et

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

9 ANSWERS REGISTRY COPYRIGHT 2002 ACS
Cholest-5-en-3-ol (3.beta.)-, (92,11E,13E,152)-9,11,13,15octadecatetraenoate (9CI)
C45 H72 O2

Absolute stereochemistry. Double bond geometry as shown.



PAGE 1-B

— (CH2) 3 CHMe2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

08945667 Page 7 09/23/2002

12 9 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 9,11,13,15-Octadecatetraenoic acid, methyl ester, (all-E)- (9CI)
MF C19 H30 O2

Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

08945667 Page 8 09/23/2002

=> s gamma linolenic acid 112172 GAMMA

1 GAMMAS

112172 GAMMA

(GAMMA OR GAMMAS)

122 LINOLENIC

5576167 ACID

7845 ACIDS

5581876 ACID

(ACID OR ACIDS)

L3 14 GAMMA LINOLENIC ACID

(GAMMA(W)LINOLENIC(W)ACID)

=> d scan

08945667 Page 9 09/23/2002

13 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 8,11,13-Eicosatrienoic acid, 15-hydroxy-, (82,112,13E)- (9CI)
MF C20 H34 O3

Double bond geometry as shown.

**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT'*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):13

L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 8,11,14-Eicosatrienoic acid, methyl ester, (82,112,142)- (9CI)
MF C21 H36 O2

Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS IN 6,9,12-Octadecatrienoic acid, methyl ester, (62,92,122) - (9CI) MF C19 H32 O2

Double bond geometry as shown.

MeO (CH2)
$$\frac{\overline{z}}{\overline{z}}$$
 \overline{z} (CH2) $\frac{\sqrt{z}}{z}$

**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT'*

L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS IN 6,9,12-Octadecatrienoic acid, ethyl ester, (62,92,122) - (9CI)

MF C20 H34 O2 CI COM

Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

08945667 Page 10 09/23/2002

Double bond geometry as shown.

PAGE 1-B

$$\sim$$
 (CH₂) $\sqrt{\frac{z}{z}}$ $\sqrt{\frac{z}{z}}$ (CH₂) $\sqrt{\frac{Me}{4}}$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 8,11,14-Eicosatrienoic acid, sodium salt, (Z,Z,Z)+ (9CI)
MF C20 H34 O2 . Na

Double bond geometry as shown.

● Na

L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 11,14-Eicosadienoic acid, methyl ester, (112,142)- (9CI)
MF C21 H38 O2

Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 6,9,12-Octadecatrienoic acid, zinc salt, (Z,Z,Z)- (9CI)
MF C18 H30 O2 . 1/2 Zn

Double bond geometry as shown.

●1/2 2n

08945667 Page 11 09/23/2002

L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 6,9,12-Octadecatrienoic acid, sodium salt, (Z,Z,Z)- (9CI)
MF C18 H30 O2 . Na

Double bond geometry as shown.

Na

L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS

N Vincaleukoblastine, 22-oxo-, mixt. with (Z,Z,Z)-6,9,12-octadecatrienoic

acid (9CI) MF C46 H56 N4 O10 . C18 H30 O2

CI MXS

CH 1

Double bond geometry as shown.

CM 2

Absolute stereochemistry.

L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 6,9,12-Octadecatrienoic acid, monoester with 1,2,3-propanetriol, (2,2,2)(9CI)
MF C21 H36 04

MF C21 H36 CI IDS

CM 1

Double bond geometry as shown.

CM 2

3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS

IN 6,9,12-Octadecatrienoic acid, (2,2,2)-, mixt. with sulfur (9CI)

MF C18 H30 O2 . S CI MXS

CH 1

s


CM 2

Double bond geometry as shown.

08945667 Page 12 09/23/2002

L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS IN 6,9,12-Octadecatrienoic acid, (6Z,9Z,12Z)- (9CI) MF C18 H30 O2 CI COM

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 14 ANSWERS REGISTRY COPYRIGHT 2002 ACS IN 0,11,14-Eicosatrienoic acid, (0Z,11Z,14Z)- (9CI) MF C20 H34 O2

CI COM

Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

08945667 Page 13 09/23/2002

```
=> s dihomo gamma linolenic acid
519 DIHOMO
112172 GAMMA
1 GAMMAS
112172 GAMMA
(GAMMA OR GAMMAS)
122 LINOLENIC
5576167 ACID
7845 ACIDS
5581876 ACID
(ACID OR ACIDS)
L4 4 DIHOMO GAMMA LINOLENIC ACID
(DIHOMO(W) GAMMA(W) LINOLENIC (W) ACID)
```

08945667 Page 14 09/23/2002

4 ANSWERS REGISTRY COPYRIGHT 2002 ACS IN 8,11,14-Eicosatrienoic acid, methyl ester, (82,112,142)- (9CI) MF C21 H36 O2

Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L4 4 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 8,11,14-Eicosatrienoic acid, (8Z,11Z,14Z) - (9CI)
MF C20 H34 O2
CI COM

Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L4 4 ANSWERS REGISTRY COPYRIGHT 2002 ACS IN 8,11,14-Eicosatrienoic acid, sodium salt, (2,2,2)- (9CI) MF C20 H34 O2 . Na

Double bond geometry as shown.

Na

L4 4 ANSWERS REGISTRY COPYRIGHT 2002 ACS IN 8,11,13-Eicosatrienoic acid, 15-hydroxy-, (8Z,11Z,13E)- (9CI) MF C20 H34 O3

Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

08945667 Page 15 09/23/2002

=> s arachidonic acid 77 ARACHIDONIC 5576167 ACID 7845 ACIDS

5581876 ACID

(ACID OR ACIDS)

L5

73 ARACHIDONIC ACID (ARACHIDONIC (W) ACID)

=> d scan

08945667 Page 16 09/23/2002

L5 73 ANSWERS REGISTRY COPYRIGHT 2002 ACS IN 5,8,11,14-Eicosatetraeneperoxoic acid, (all-Z)- (9CI) MF C20 H32 O3

Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):9

L5 73 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 5,8,11,14-Eicosatetraenoic acid, hydroxy-, (52,82,112,142)- (9C1)
MF C20 H32 O3
CI IDS

PAGE 1-A HO2C- (CH2) 3-CH=CH-CH2-CH=CH-CH2-CH=CH-CH2-CH=CH-

D1-OH

PAGE 1-B

— (СН₂) 4-Me

L5 73 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 5,8,11,14-Eicosatetraenoic acid, 2,2-dimethyl-, (5Z,8Z,11Z,14Z)- (9CI)
MF C22 H36 O2

Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 73 ANSWERS REGISTRY COPYRIGHT 2002 ACS IN 5,8,11,14-Eicosatetraenoic acid, 19-oxo-, (all-2)- (9CI) MF C20 H30 O3


Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

08945667 Page 17 09/23/2002

L5 73 ANSWERS REGISTRY COPYRIGHT 2002 ACS IN 5,8,11-Eicosatrien-14-ynoic acid, (Z,Z,Z)- (9CI) MF C20 H30 O2

Double bond geometry as shown.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT **

L5 73 ANSWERS REGISTRY COPYRIGHT 2002 ACS IN 5,8,11,14-Eicosatetraenoic acid, labeled with carbon-14, (all-Z)- (9CI)

MF C20 H32 O2

Double bond geometry as shown.

73 ANSWERS REGISTRY COPYRIGHT 2002 ACS
Kinase (phosphorylating), PKB (Xenopus laevis clone X3 arachidonic

acid-binding) (9CI)

SQL 901

MF Unspecified

CI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

L5 73 ANSWERS REGISTRY COPYRIGHT 2002 ACS

IN Oxygenase, arachidonate 18-mono- (9CI) Unspecified

MF CI MAN

^{***} STRUCTURE DIAGRAM IS NOT AVAILABLE ***

08945667 Page 18 09/23/2002

L5 73 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 5,8,11,14-Eicosatetraenamide-N-t, N-(2-hydroxyethyl-1,1-t2)-, (all-Z)-

(9CI) MF C22 H34 N O2 T3

Double bond geometry as shown.

PAGE 1-B

L5 73 ANSWERS REGISTRY COPYRIGHT 2002 ACS

DEA (human potassium channel TRAAK (TWIK-related arachidonic acid-stimulated K channel) cDMA) (9CI)

SQL 1182

MF Unspecified CI MAN

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

08945667 Page 19 09/23/2002

=> s stearidonic acid

2 STEARIDONIC

5576167 ACID 7845 ACIDS 5581876 ACID

(ACID OR ACIDS)

L6 2 STEARIDONIC ACID

(STEARIDONIC (W) ACID)

=> d scan

08945667 Page 20 09/23/2002

L6 2 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 6,9,12,15-Octadecatetraenoic acid, (62,92,122,152) - (9CI)
MF C18 H28 O2
CI COM

Double bond geometry as shown.


$$\begin{array}{c|c}
\hline
z\\
\hline
\hline
z\\
\hline
\end{array}$$
(CH2) $\stackrel{CO_2H}{\longleftarrow}$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 2 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 8,11,14,17-Eicosatetraenoic acid, (8Z,11Z,14Z,17Z)- (9CI)
MF C20 H32 O2
CI COM

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

08945667 Page 21 09/23/2002

=> s eicosapentaenoic acid

827 EICOSAPENTAENOIC

5576167 ACID 7845 ACIDS 5581876 ACID

(ACID OR ACIDS)

L7

811 EICOSAPENTAENOIC ACID

(EICOSAPENTAENOIC (W) ACID)

=> d scan

08945667 Page 22 09/23/2002

L7 B11 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 5,8,11,14,17-Eicosapentaenoic acid, (25)-3-hydroxy-2-{[(91)-1-0x0-9octadecenyl]oxy]propyl ester, (52,82,112,142,172)- (9CI) C41 H68 O5

Absolute stereochemistry. Double bond geometry as shown.

PAGE 1-B

$$\overline{z}$$
 \overline{z} z Et

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):9

811 ANSWERS REGISTRY COPYRIGHT 2002 ACS 5,8,11,14,17-Eicosapentaenoic acid, octadecyl ester, (5E,8E,11E,14E,17E)- (9CI) C38 H66 O2

Double bond geometry as shown.

PAGE 1-B

- (CH₂) 17 Me

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 811 ANSWERS REGISTRY COPYRIGHT 2002 ACS IN 5,8,11,14,17-Eicosapentaenoic acid, (28)-3-[[(2aminoethoxy)hydroxyphosphinyl]oxy]-2-[[(112,142)-1-oxo-11,14eicosadienyl]oxy]propyl ester, (52,62,112,142,172) - (9CI) MF C45 H76 N 08 P

Absolute stereochemistry. Double bond geometry as shown.

PAGE 1-B

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 811 ANSWERS REGISTRY COPYRIGHT 2002 ACS
- Elcosapentaenoic acid, 2-[(1-oxohexadecyl)oxy]-1,3-propanediyl ester IN
- (9CI) С59 Н94 О6 MF
- IDS

CH 1

08945667 Page 23 09/23/2002

L7 811 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 5,8,11,14,17-Eicosapentaenoic acid, 16-hydroxy-, (all-1)- (9CI)
MF C20 H30 O3

Double bond geometry as shown.

$$\begin{array}{c|c}
\hline
z \\
\hline
\hline
z \\
\hline
\hline
z
\end{array}$$

$$\begin{array}{c}
\hline
\hline
z \\
\hline
\hline
z
\end{array}$$

$$\begin{array}{c}
\hline
\hline
z \\
\hline
\hline
z
\end{array}$$

$$\begin{array}{c}
\hline
\hline
z \\
\hline
\hline
z
\end{array}$$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 811 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 6,9,12,15,18-Eicosapentaenoic acid, labeled with deuterium, (all-Z)(9CI)
MF C20 H30 O2

Double bond geometry as shown.

L7 811 ANSWERS REGISTRY COPYRIGHT 2002 ACS IN Bicosapentaenoic acid, bexacosyl ester (9CI) MF C46 H82 O2 CI IDS

CM 1

0 || Me- (CH₂)₂₅-0-C- (CH₂)₁₈-Me

L7 811 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 5,8,12,14,17-Eicosapentaenoic acid, 11-hydroperoxy-, (E,Z,Z,Z,Z)(9CI)
MF C20 H30 O4

Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

08945667 Page 24 09/23/2002

L7 811 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 5,8,11,14,17-Bicosapentaenoic acid, ester with 1,2,3-propanetriol monodocosenoate monohexadecanoate, (all-I)- (9CI)

C61 H106 O6

CI IDS

CH 1

Double bond geometry as shown.

CH 2

 $HO_2C - (CH_2)_{14} - Me$

CH 3

CM 4

CH 5

 $HO_2C - (CH_2)_{20} - Me$

L7 811 ANSWERS REGISTRY COPYRIGHT 2002 ACS 5,8,10,14,17-Eicosapentaenoic acid, 12,13-dihydroxy-,

[S-[R*,S*-(I,E,I,I,I)]]- (9CI)

C20 H30 O4

Absolute stereochemistry. Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

08945667 Page 25 09/23/2002

```
=> s docosapentaenoic acid n-3
           275 DOCOSAPENTAENOIC
       5576167 ACID
          7845 ACIDS
       5581876 ACID
                 (ACID OR ACIDS)
       4275795 N
      11229525 3
L8
             0 DOCOSAPENTAENOIC ACID N-3
                 (DOCOSAPENTAENOIC(W)ACID(W)N(W)3)
=> s docosapentaenoic acid
           275 DOCOSAPENTAENOIC
       5576167 ACID
          7845 ACIDS
       5581876 ACID
                 (ACID OR ACIDS)
           269 DOCOSAPENTAENOIC ACID
L9
                 (DOCOSAPENTAENOIC (W) ACID)
=> d scan
```

08945667 Page 26 09/23/2002

L9 269 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 7,10,12,15,19-Docommentaenoic acid, 17-bydroperoxy-14-bydroxy(9CI)

MF C22 H34 O5

PAGE 1-A

PAGE 1-B

- (CH₂) 5-CO₂H

**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT'*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):9

L9 269 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Docosapentaenoic acid, ester with 1,2,3-propanetriol 1-(2-aminoethyl hydrogen phosphate) mono-(Z)-hexadecenoate, (Z,Z,Z,Z)- (9CI)
MF C43 H74 N O8 P

CI IDS

CH 1

CPI 2

CM 3

HO₂C - (CH₂)₂₀-Me

CH 4 CH 5

HO₂C- (CH₂)₁₄-Me

Absolute stereochemistry.

Double bond geometry as shown.

**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT **

Absolute stereochemistry.

Double bond geometry as described by E or 2.

PAGE 1-B

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

08945667 Page 27 09/23/2002

L9 269 ANSWERS REGISTRY COPYRIGHT 2002 ACS IN 7,10,12,16,19-Docosapentaenoic acid, 14-hydroxy- (9CI) MF C22 H34 O3

PAGE 1-A

PAGE 1-B

- (CH₂)₅-CO₂H

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 269 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 7,10,13,16,19-Docosapentaenoic acid, 1-(hydroxymethyl)-2-[(1-oxooctadecyl)oxy)ethyl ester, [R-(all-2)]- (9CI)
MF C43 H74 O5

Absolute stereochemistry. Double bond geometry as shown.

PAGE 1-B

Z

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 269 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4,7,10,13,16-Docosapentaenoic acid, 1-[[[(2aminoethoxy)hydroxyphosphinyl]oxy]methyl]-2-[(1-oxooctadecyl)oxy]ethyl
ester (9CI)
MF C45 H80 N O8 P
CI COM

PAGE 1-B

= CH- CH2- CH= CH- CH2- CH= CH- CH2- CH= CH- (CH2) 4-Me

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 269 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4,7,10,13,16-Docosapentaenoic acid, 1-[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-2-[(1-oxo-7,10,13,16-docosatetraenyl)oxy]ethyl ester, (all-2)- (9CI)
MF C49 H80 N O8 P

Double bond geometry as shown.

PAGE 1-B

PAGE 1-C

` Me

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

Examiner Anderson 703-605-1157

08945667 Page 28 09/23/2002

L9 269 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4,7,10,13,19-Docosapentaenoic acid, 14-hydroperoxy- (9CI)
MF C22 H34 O4

PAGE 1-A

0-0H | | | Et-CH=CH-(CH₂)₄-C=CH-CH₂-CH=CH-CH₂-CH=CH-CH₂-CH=

PAGE 1-B

= CH- CH $_2-$ CH $_2-$ CO $_2$ H

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L9 269 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Docosapentaenoic acid, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]meth
y1]-2-(9-octadecenyloxy)ethyl ester, [R-(all-z)]- (9CI)
MF C45 H80 N 07 P
CI IDS

CH 1

Absolute stereochemistry.

Double bond geometry as shown.

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

08945667 Page 29 09/23/2002

=> s docosahexaenoic acid

693 DOCOSAHEXAENOIC

5576167 ACID 7845 ACIDS 5581876 ACID

(ACID OR ACIDS)

L10

688 DOCOSAHEXAENOIC ACID

(DOCOSAHEXAENOIC (W) ACID)


=> d scan

08945667 Page 30 09/23/2002

L10 688 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4,7,10,13,16,19-Docosahaxaenoic acid, monoester with
1,2,3-propanetriol monooctanoate, (42,72,102,132,162,192)- (9CI)
MF C33 H52 O5
CI IDS

CH 1

Double bond geometry as shown.



CH 2

HO2C- (CH2) 6-Me

CM 3

ОН | | НО- СН₂- СН- СН₂- ОН

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):9

L10 688 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4,7,10,13,16,19-Docosahexaenoic acid, (1R)-1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-2-[[(92)-1-oxo-9-hexadecenyl]oxy]ethyl ester, (4Z,7Z,10Z,13Z,16Z,19Z)- (9CI)
MF C43 H72 N O8 P

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-B

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

Double bond geometry as shown.

PAGE 1-A

MeO (CH₂)
$$\frac{1}{3}$$
 $\frac{1}{2}$ $\frac{1}{2}$ $\frac{1}{2}$ $\frac{1}{2}$ $\frac{1}{2}$

PAGE 1-B

L10 688 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4,7,10,13,16,19-Docosahexaenoic acid, ester with 1,2,3-propanetriol dihexadecadienoate, (all-z)- (9CI)
MF C57 H94 O6
CI IDS

CM 1

Double bond geometry as shown

$$\overline{z}$$
 \overline{z} \overline{z} \overline{z} \overline{z} \overline{z} \overline{z}

CPH 2

CM 3

CM 4


HO₂C- (CH₂) 14-Me

08945667 Page 31 09/23/2002

L10 688 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4,7,10,13,16,19-Docosahexaenoic acid, monoester with
1,2,3-propanetriol monooctadecanoate, [8-(all-z)]- (9CI)
MF C43 H72 O5
CI IDS

CH 1

Double bond geometry as shown.



CN 2

HO₂C- (CH₂)₁₆-Me

CM 3

OH | | HO-CH2-CH-CH2-OH

L10 688 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4,7,10,13,16,19-Docosahexaenoic acid, 3-({(2-aminoethoxy)hydroxyphosphinyl]oxy}-2-{(1-oxo-4,7,10,13,16-docosapentaenyl)oxy}propyl ester, (all-2)- (9CI)
MF C49 H76 N O8 P

Double bond geometry as shown.

PAGE 1-B

PAGE 1-C

Z (CH2) 4 Me

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 688 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4,7,10,13,16,19-Docosahexaenoic acid, 2-[(1-oxo-9,12-octadecadienyl)oxy]-3-[(1-oxo-9-octadecanyl)oxy]propyl ester, (all-z)-(9CI)
MF C61 H100 O6

Double bond geometry as shown.

PAGE 1-B

PAGE 1-A

$$\overline{z}$$
 \overline{z} \overline{z} \overline{z}

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 688 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4,7,10,13,16,19-Docosahexaenoic acid, (18)-1-(hydroxymethyl)-1,2-ethanediyl ester, (42,4'z,72,7'z,10z,10'z,13z,13'z,16z,16'z,19z,19'z)-(9CI)

MF C47 H68 05

Absolute stereochemistry. Double bond geometry as shown.

$$\underbrace{\overline{z}}_{\text{Et}}$$

PAGE 1-B

PAGE 1-C

. **PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

08945667 Page 32 09/23/2002

L10 688 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4,7,10,13,16,19-Docosahexaenoic acid, monoester with
1,2,3-propanetriol monohexadecanoate mono-(9%)-9-hexadecenoate,
(4%,7%,10%,13%,16%,19%)- (9CI)
MF CS7 H96 06

CI IDS

CH 1

Double bond geometry as shown.

CH 2

Double bond geometry as shown.

CM 3

 $HO_2C-(CH_2)_{14}-Me$

CH 4

L10 688 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 4,7,10,13,15,19-Docosahexaenoic acid, 17-(benzoyloxy)-, methyl ester,
{s-(4z,7z,10z,13z,15z,19z)}- (9CI)
MF C30 H38 O4

Absolute stereochemistry. Rotation (+). Double bond geometry as shown.

PAGE 1-A

Et
Z
S
E
Z
Z
Z
O

PAGE 1-B

_OMe

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

08945667 Page 33 09/23/2002

=> s columbinic acid

3 COLUMBINIC

5576167 ACID 7845 ACIDS 5581876 ACID

(ACID OR ACIDS)

L11

3 COLUMBINIC ACID

(COLUMBINIC (W) ACID)

=> d scan

08945667 Page 34 09/23/2002

Lll 3 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Cholest-5-en-3-ol (3.beta.)-, 5,9,12-octadecatrienoate, (Z,Z,E)- (9CI)
MF C45 H74 O2

PAGE 1-A

PAGE 1-B

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L11 3 ANSWERS REGISTRY COPYRIGHT 2002 ACS IN 7,11,14-Eicosatrienoic acid, (7E,112,14Z) - (9CI) MF C20 H34 O2

Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

L11 3 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 5,9,12-Octadecatrienoic acid, (5E,9Z,12Z)- (9CI)
MF C18 H30 O2
CI COM

Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

08945667 Page 35 09/23/2002

=> s conjugated linoleic acid

130 CONJUGATED

514 LINOLEIC

5576167 ACID

7845 ACIDS

5581876 ACID

(ACID OR ACIDS)

L12

7 CONJUGATED LINOLEIC ACID

(CONJUGATED (W) LINOLEIC (W) ACID)

=> d scan

08945667 Page 36 09/23/2002

L12 7 ANSWERS REGISTRY COPYRIGHT 2002 ACS IN 9,11-Octadecadienoic acid (6CI, 8CI, 9CI) MF C18 H32 O2

CI COM

 $HO_2C-(CH_2)_7-CH=CH-CH=CH-(CH_2)_5-Me$

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):6

L12 7 ANSWERS REGISTRY COPYRIGHT 2002 ACS IN Fatty acids, C16-18 and C18-unsatd., polymers with benzoic acid, conjugated linoleic acid, diethylene glycol, isophthalic acid, oleic acid, trimellitic anhydride, trimethylolethane and trimethylolpropane

Unspecified CI MAN, CTS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L12 7 ANSWERS REGISTRY COPYRIGHT 2002 ACS IN Fatty acids, tall-oil, polymers with bisphenol A, conjugated linoleic acid, epichlorohydrin and maleic anhydride MF Unspecified CI PMS, MAN, CTS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L12 7 ANSWERS REGISTRY COPYRIGHT 2002 ACS IN 9,11-Octadecadienoic acid, (92,11E) - (9CI) MF C18 H32 O2 CI COM

Double bond geometry as shown.

HO₂C (CH₂) 7 Z E (CH₂) 5 Me

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

08945667 Page 37 09/23/2002

L12 7 ANSWERS REGISTRY COPYRIGHT 2002 ACS IN Octadecadienoic acid (9CI) MF C18 H32 O2 CI IDS, COM

CH 1

 ${
m HO_2C-(CH_2)_{16}-Me}$

L12 7 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 10,12-Octadecadienoic acid, (10E,122) - (9CI)
MF C18 H32 O2
CI COM

Double bond geometry as shown.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 7 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Castor oil, polymer with conjugated linoleic acid, glycerol and phthalic anhydride
MF Unspecified
CI PMS, MAN, CTS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

ALL ANSWERS HAVE BEEN SCANNED

08945667 Page 38 09/23/2002

=> fil caplus
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 124.24 124.45

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 07:52:57 ON 23 SEP 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Sep 2002 VOL 137 ISS 13 FILE LAST UPDATED: 22 Sep 2002 (20020922/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d his

(FILE 'HOME' ENTERED AT 07:48:37 ON 23 SEP 2002)

```
FILE 'REGISTRY' ENTERED AT 07:48:44 ON 23 SEP 2002
L1
              1 S ADRENIC ACID
              9 S PARINARIC ACID
L2
             14 S GAMMA LINOLENIC ACID
L3
              4 S DIHOMO GAMMA LINOLENIC ACID
L4
L5
             73 S ARACHIDONIC ACID
L6
              2 S STEARIDONIC ACID
            811 S EICOSAPENTAENOIC ACID
L7
              0 S DOCOSAPENTAENOIC ACID N-3
L8
L9
            269 S DOCOSAPENTAENOIC ACID
L10
            688 S DOCOSAHEXAENOIC ACID
L11
              3 S COLUMBINIC ACID
L12
              7 S CONJUGATED LINOLEIC ACID
```

FILE 'CAPLUS' ENTERED AT 07:52:57 ON 23 SEP 2002

=> s 11 L13 160 L1

=> s 11 and 12

08945667 Page 39 09/23/2002

160 L1 239 L2

L14 2 L1 AND L2

=> d ibib abs hitstr 1-2

08945667 Page 40 09/23/2002

```
L14 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER:
                        1997:26284 CAPLUS
DOCUMENT NUMBER:
TITLE:
                         Preparation of 1,3-propanediol derivatives for
                         transport of bioactive compounds
INVENTOR(5):
                         Horrobin, David Frederick: Manku, Mehar: Mcmordie,
                        Austin; Knowles, Philip; Redden, Peter; Pitt, Andrea;
                         Bradley, Paul; Wakefield, Paul
PATENT ASSIGNEE(S):
                         Scotia Holdings Plc, UK; Horrobin, David Frederick;
                         Manku, Mehar: Mcmordie, Austin: Knowles, Philip:
                         Redden, Peter: Pitt, Andrea: Bradley, Paul: Wakefield,
                         Paul
                        PCT Int. Appl., 78 pp.
SOURCE:
                         CODEN: PIXXD2
DOCUMENT TYPE:
                        Patent
LANGUAGE:
                         English
FAMILY ACC. NUM. COUNT:
                        3
PATENT INFORMATION:
    PATENT NO.
                     KIND DATE
                                          APPLICATION NO. DATE
                                          WO 1996-GB1053 19960501
    WO 9634846
                      Al 19961107
        W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI,
             GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD,
             MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ,
        RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
             IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,
             MR, NE, SN, TD, TG
    ZA 9603360
                                          2A 1996-3360
                           19960820
                                                           19960426
                      Α
    ZA 9603397
                                                           19960429
                      Α
                           19960807
                                          ZA 1996-3397
    ZA 9603433
                           19960807
                                          ZA 1996-3433
                                                           19960430
                      Α
                           19961107
                                          CA 1996-2218699 19960501
    CA 2218699
                           19961107
    CA 2218702
                      AA
                                          CA 1996-2218702 19960501
    AU 9655080
                      A1
                           19961121
                                          AU 1996-55080
                                                          19960501
    AU 707600
                           19990715
                      B2
    EP 823889
                          19980218
                                          EP 1996-912139 19960501
                      A1
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
            SI, LT, LV, FI
    CN 1187813
                           19980715
                                          CN 1996-194780 19960501
                      Α
                                                          19960501
    CN 1189148
                           19980729
                                          CN 1996-195062
                      Α
    BR 9606607
                                          BR 1996-6607
                           19981215
                                                           19960501
    JP 11504914
                      T2
                           19990511
                                          JP 1996-533121
                                                          19960501
    NO 9705036
                      A
                           19971217
                                          NO 1997-5036
                                                           19971031
                                                      A 19950501
PRIORITY APPLN. INFO.:
                                       GB 1995-8823
                                       GB 1995-17107
                                                      A 19950821
                                                        A 19960315
                                       GB 1996-5440
                                       WO 1996-GB1053 W 19960501
   The prepn. of 1,3-propanediol derivs., R10CH2CH2CH2CH2 (R1 is an acyl or
    fatty alc. group derived from a Cl2-30 preferably a Cl6-30 fatty acid
    desirably with two or more cis or trans double bonds, and R2 is hydrogen,
    or an acyl or fatty alc. group the same as or different, from R1 or any
    other nutrient, drug or other bioactive residue) for use in therapy are
    described. Title compds. are prepd. via acylation of 1,3-propanediol with
```

```
L14 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER:
                        1996:740363 CAPLUS
DOCUMENT NUMBER:
                        126:11535
                         Fatty acid salts of N-methylqlucamine
TITLE:
INVENTOR(S):
                        Horrobin, David Frederick; Knowles, Philip; Manku,
                        Mehar: Bonnett, Raymond; Stewart, John Charles
                        Marshall
PATENT ASSIGNEE(S):
                        Scotia Holdings PLC, UK
                        PCT Int. Appl., 14 pp.
SOURCE:
                        CODEN: PIXXD2
DOCUMENT TYPE:
                        Patent
LANGUAGE:
                        English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
    PATENT NO.
                     KIND DATE
                                          APPLICATION NO. DATE
```

a fatty acid followed by reaction with a bioactive compd. Title compds. are capable of crossing lipid membranes as in the skin and blood-brain

										_									
	WO 9	633	155		A	1	1996	1024		W	0 19	96-G	в952		1996	0419			
							BG,											FI.	
							JP,												
							NO,												
			TM,			,			,	,	,	-10,	,	,	,	,	,	,	
		R¥:	-		MW.	SD.	SZ,	UG.	AT.	BE.	CH.	DE.	DK.	ES.	FI.	FR.	GB.	GR.	
							NL,												
				NE,				,		,	,	,	,	,	ш.,	,	•,	,	
	ZA 9	603					1996	0830		2.7	A 19	96-3	103		1996	N418			
	CA 2	218	636				1996												
	AU 9														1996				
	AU 7	166	80		B	2	2000	0302											
	BR 9	606								В	R 19	96-6	509		19960	0419			
	EP 8						1998												
		R:					DK,										PT.	IE.	FI
	JP 1	1503	3747	•	T	?	1999	0330	,	JI	199	96-53	3156	9 '	19960	0419	,	,	
	US 5																		
PRIO	RITY .														19950				
															19960				
AB	N-me	thy?	lglud	cami	ne sa	ılts	of s	ooly									vi na	16 :	to.
							to si												
							ion,												
	wate	r-50	ol. d	deriv	/3. V	rith	imp	rove	fo:	rmula	atio	n pro	per'	ties	. T	hus.		_	
	N-me																	salt	Ŀ.
IT	593-	38-4	١,	alpha	aPa	rin	aric	acio	1 209	1-25	i-0,	Adre	enic	aci	d ¯	-			
	RL:																		
	(1	prep	on. 0	of N-	metl	ylq	lucar	aine	sali	to of	un	atd.	fai	ttv	acida	9)			
RN	593-													- 4		•			

9,11,13,15-Octadecatetraenoic acid, (92,11E,13E,152)- (9CI) (CA INDEX

Double bond geometry as shown.

RN 2091-25-0 CAPLUS CN 7,10,13,16-Docosatetraenoic acid (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

Examiner Anderson 703-605-1157

PAGE 1-B

— (CH₂) ₄ - Ме

=> d his

```
(FILE 'HOME' ENTERED AT 07:48:37 ON 23 SEP 2002)
```

```
FILE 'REGISTRY' ENTERED AT 07:48:44 ON 23 SEP 2002
             1 S ADRENIC ACID
L1
             9 S PARINARIC ACID
L2
            14 S GAMMA LINOLENIC ACID
L3
            4 S DIHOMO GAMMA LINOLENIC ACID
L4
          73 S ARACHIDONIC ACID
L5
           2 S STEARIDONIC ACID
L6
L7
        811 S EICOSAPENTAENOIC ACID
rac{1}{2}
           0 S DOCOSAPENTAENOIC ACID N-3
          269 S DOCOSAPENTAENOIC ACID
L9
          688 S DOCOSAHEXAENOIC ACID
L10
           3 S COLUMBINIC ACID
L11
             7 S CONJUGATED LINOLEIC ACID
L12
     FILE 'CAPLUS' ENTERED AT 07:52:57 ON 23 SEP 2002
L13
          160 S L1
L14
           2 S L1 AND L2
=> s 12
    239 L2
L15
=> s 13
L16 4896 L3
=> s 14
L17
         2711 L4
=> s 15
L18 35302 L5
=> s 16
L19
         1294 L6
=> s 17
L20
         8982 L7
=> s 19
L21
         3640 L9
=> s 110
L22
         9802 L10
=> s 111
L23
           46 L11
=> s 112
L24
          759 L12
=> s 12 and 13
          239 L2
         4896 L3
L25
           17 L2 AND L3
```

08945667 Page 42 09/23/2002

=> s 125 and 14

2711 L4 L26 7 L25 AND L4

=> s 126 and 15

35302 L5

L27 6 L26 AND L5

=> s 127 and 16

1294 L6

L28 2 L27 AND L6

=> s 128 not 114

L29 1 L28 NOT L14

=> d ibib abs hitstr

08945667 Page 43 09/23/2002

L29 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS 1994:465570 CAPLUS ACCESSION NUMBER: DOCUMENT NUMBER: 121:65570 Pharmaceutical compositions containing fatty acids and TITLE: Horrobin, David F.; Scott, Catherine A. INVENTOR(S): PATENT ASSIGNEE(S): Scotia Holdings PLC, UK Eur. Pat. Appl., 9 pp. SOURCE: CODEN: EPXXOW DOCUMENT TYPE: Patent LANGUAGE: English FAMILY ACC. NUM. COUNT: PATENT INFORMATION: KIND DATE PATENT NO. APPLICATION NO. DATE A1 19940302 EP 1993-306570 19930819 EP 585058 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE AU 1993-44807 19930823 AU 9344807 A1 19940303 AU 666961 B2 19960229 CA 2104747 λA 19940226 CA 1993-2104747 19930824 NO 9303017 73017 סא 19930824 19940228 Α JP 06157305 A2 19940603 JP 1993-209487 19930824 ZA 9306232 19940321 ZA 1993-6232 19930825 CN 1090776 19940817 CN 1993-118329 19930825 PRIORITY APPLN. INFO.: GB 1992-18065 19920825 GB 1992-22655 19921028 AB A method of safe i.v. administration of fatty acids or salts and derivs. thereof or conjugated fatty acids, is comprised of i.v. or sub-cutaneous administration of heparin (I) in a dose of 1,000-20,000 IU, preferably 3000-10,000 IU or equiv. anticoagulant dose of I-like proteins or peptides prior to infusion of the fatty acids. This method is useful in the treatment of cancer, viral infections and other disorders, requiring maintenance of high plasma fatty acid levels. Ampules contg. a soln. of 5-500mg/mL Li .gamma.-linolenate in 0.9% saline soln. were prepd. which could be added to i.v. fluids to achieve final concn. of 5-20mg/mL to patients pretreated with I at a dose of 3000-10,000IU. IT 506-26-3, .gamma.-Linolenic acid 506-32-1, Arachidonic acid 1783-84-2, Dihomo-.gamma.-linolenic acid 18427-44-6 , Parinaric acid 20290-75-9, Stearidonic acid RL: BIOL (Biological study) (pharmaceutical compn. contg., heparin for safe administration of) 506-26-3 CAPLUS 6,9,12-Octadecatrienoic acid, (6Z,9Z,12Z)- (9CI) (CA INDEX NAME) Double bond geometry as shown.

506-32-1 CAPLUS 5,8,11,14-Eicosatetraenoic acid, (5Z,8Z,11Z,14Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L29 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS (Continued)

1783-84-2 CAPLUS 8,11,14-Eicosatrienoic acid, (82,112,142)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

Double bond geometry as shown.

18427-44-6 CAPLUS 9,11,13,15-Octadecatetraenoic acid (7CI, 8CI, 9CI) (CA INDEX NAME)

HO2C- (CH2) 7-CH=CH-CH=CH-CH=CH-CH=Et

RN 20290-75-9 CAPLUS CN 6,9,12,15-Octadecatetraenoic acid, (62,92,122,152) - (9CI) (CA INDEX NAME)

CO2H

08945667 Page 44 09/23/2002

=> d ibib abs hitstr 125 1-17

08945667 Page 45 09/23/2002

L25 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: DOCUMENT NUMBER:

TITLE:

2002:466707 CAPLUS

137:37683

Method of potentiating the action of 2-methoxyoestradiol, statins and c-peptide of

proinsulin Das, Undurti Narasimha

PATENT ASSIGNEE(S): SOURCE:

INVENTOR(S):

USA U.S. Pat. Appl. Publ., 15 pp.

CODEN: USXXCO Patent

DOCUMENT TYPE: LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ----

US 2002077317 A1 20020620 US 2000-737671 20001215 Disclosed is a method of stabilizing and potentiating the actions of 2-methoxyoestradiol, statins, H2 blockers, and C-peptide of proinsulin which have modifying influence on angiogenesis and inhibiting the growth of tumor cells, peptic ulcer disease, diabetes mellitus and its complications, and Alzheimer's disease as applicable by using in coupling conjugation certain polyunsatd. fatty acids (PUFAs) chosen from linoleic acid, .gamma.-linolenic acid, dihomo-.gamma.-linolenic acid, arachidonic acid, .alpha.-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, cis-parinaric acid or conjugated linoleic acid in predetd. quantities. Uncontrolled angiogenic activity and tumor growth can be inhibited by the selective use of a mixt. of PUFAs with anti-angiogenic substances used selectively, and optionally in conjunction with predetd. anti-cancer drugs. A preferred method of administration of the mixt. to treat a tumor is intra-arterial administration into an artery which provides the main blood supply for the tumor. The method will also be useful in the treatment of peptic ulcer disease, diabetes mellitus and its complications and Alzheimer's disease.

506-26-3, .gamma.-Linolenic acid 593-38-4, cis-Parinaric

acid 1783-84-2, Dihomo-.gamma.-linolenic acid

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (polyunsatd, fatty acids for potentiating actions of anigogenesis inhibitors and antiulcer agents and antidiabetics and mental disease drugs)

506-26-3 CAPLUS

6,9,12-Octadecatrienoic acid, (62,92,122) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

593-38-4 CAPLUS

9,11,13,15-Octadecatetraenoic acid, (9Z,11E,13E,15Z)- (9CI) (CA INDEX

Double bond geometry as shown.

L25 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2001:545113 CAPLUS

DOCUMENT NUMBER:

TITLE:

Lipid and fatty acid analysis of fresh and frozen-thawed immature and in vitro matured bovine oocytes

AUTHOR (S): CORPORATE SOURCE:

Kim, J. Y.; Kinoshita, M.; Ohnishi, M.; Fukui, Y. Laboratory of Animal Genetics and Reproduction, Obihiro University of Agriculture and Veterinary

SOURCE:

Reproduction (Cambridge, United Kingdom) (2001), 122(1), 131-138

Medicine, Obihiro, 080-8555, Japan

CODEN: RCUKBS; ISSN: 1470-1626

PUBLISHER: Journals of Reproduction and Fertility Ltd.

DOCUMENT TYPE: Journal LANGUAGE:

English AB The lipid content and fatty acid compn. of fresh immature and in vitro matured bovine oocytes cultured in media with or without serum, and also those of frozen-thawed immature occytes were analyzed. All occytes were ranked (A or B) on the basis of their cytoplasmic quality. Fatty acid compn. (mol %; wt./wt.) in the total lipid fraction was analyzed by gas chromatog. Triglyceride, total cholesterol, phospholipid (phosphocholine-contg. phospholipid) and non-esterified fatty acid contents of immature and in vitro matured oocytes were detd. using lipid anal. kits. Phosphocholine-contg. phospholipid and non-esterified fatty acid contents were detd. in frozen-thawed immature bovine occytes. Palmitic acid was the most abundant fatty acid in immature cocytes (A: 35%, B: 36%), and in in vitro matured oocytes cultured in the medium contg. serum (A: 361, B: 351) or polyvinyl alc. (A: 331, B: 361). Oleic acid was the second most abundant fatty acid in all A ranked oocytes, whereas stearic acid was the second most abundant fatty acid in all B ranked occytes. There were significant differences (P < 0.05) in linoleic and arachidonic acid fractions between A and B ranked immature occytes. In vitro matured occytes had significantly (P < 0.05) lower proportions of linoleic and arachidonic acids, and significantly (P < 0.01) lower contents of triglyceride and total cholesterol compared with those of immature oocytes. The fatty acid compn. of in vitro matured oocytes cultured in medium contg. fetal calf serum or polyvinyl alc. was similar, but significant differences (P < 0.01) in triglyceride and the total cholesterol content were obsd. There was a significant decrease (P < 0.05) in the arachidonic acid proportion in frozen-thawed immature occytes compared with that in fresh immature oocytes. In addn., significant (P < 0.05) decreases in both phospholipid (15.8-10.6 pmol) and non-esterified fatty acid (11.0-4.1 pmol) were found in frozen-thawed immature occytes. The results indicate that lipids are available for use as an energy source for maturation and that serum lipids are incorporated into the cocyte cytoplasm during in vitro maturation. The changes in the lipid content (mainly phospholipid) and fatty acid compn. were also obsd. in frozen-thawed immature oocytes. The study indicates that the alteration of fatty acid compn. in bovine occytes might improve maturation and cryopreservation.

506-26-3, .gamma.-Linolenic acid 1783-84-2

18427-44-6, Parinaric acid

RL: BOC (Biological occurrence); BSU (Biological study, unclassified);

BIOL (Biological study): OCCU (Occurrence) (lipid and fatty acid anal. of fresh and frozen-thawed immature and in vitro matured bovine oocytes)

506-26-3 CAPLUS

6,9,12-Octadecatrienoic acid, (6Z,9Z,12Z) - (9CI) (CA INDEX NAME)

Examiner Anderson 703-605-1157

L25 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)

1783-84-2 CAPLUS

8,11,14-Eicosatrienoic acid, (8Z,11Z,14Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L25 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued) Double bond geometry as shown.

1783-84-2 CAPLUS RN 8,11,14-Eicosatrienoic acid, (8Z,11Z,14Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

$$(CH_2)_6$$
 Z Z $(CH_2)_4$ Me

18427-44-6 CAPLUS 9,11,13,15-Octadecatetraenoic acid (7CI, 8CI, 9CI) (CA INDEX NAME)

HO₂C- (CH₂)₇-CH=CH-CH=CH-CH=CH-CH=CH-Et

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

08945667 Page 46 09/23/2002

```
L25 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER:
                         2001:507528 CAPLUS
DOCUMENT NUMBER:
                         135:97483
                         Composition for stabilizing and potentiating the
TITLE:
                         action of anti-angiogenic substances by
                         polyunsaturated fatty acids
                         Das, Undurti N.
INVENTOR(S):
PATENT ASSIGNEE (5):
                         EFA Sciences LLC, USA
SOURCE:
                         PCT Int. Appl., 60 pp.
                        CODEN: PIXXD2
DOCUMENT TYPE:
                        Patent
LANGUAGE:
                         English
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
    PATENT NO.
                                          APPLICATION NO. DATE
    WO 2001049284
                      A1 20010712
                                          WO 2000-US1037 20000118
        W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
            DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
             KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
            MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
            TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                      B1 20020430
                                          US 2000-478291 20000105
    US 6380253
PRIORITY APPLN. INFO.:
                                       US 2000-478291 A 20000105
    Disclosed is a method of stabilizing and potentiating action of mols. of
    known anti-angiogenic substances such as Angiostatin or Endostatin by
    using in coupling conjugation with cis-unsatd. fatty acids (c-UFAs) in the
     treatment of cell proliferative disorders uses c-UFAs chosen from linoleic
    acid, .gamma.-linolenic acid, dihomo-.gamma.-linolenic acid, arachidonic
     acid, .alpha.-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid
    and cis-parinaric acid in predetd. quantities. Preferably, the c-UFAs are
    in the form of polyunsatd, fatty acids (PUFAs). Uncontrolled or
    undesirable angiogenic activity promotes cell proliferative disorders and
    tumor growth, which can be inhibited by the selective use of PUFAs with
    anti-angiogenic substances used selectively in conjunction with predetd.
    anti-cancer drugs. For treatment of glioma, a sodium salt of a PUFA is
    preferred to form an admixt. with an anti-angiogenic substance and a
    selected anti-cancer drug. For a non-glioma type of cell proliferation
    disorder, a sodium, potassium or lithium salt of a PUFA is preferred to
    form an admixt. with an anti-angiogenic substance. Anti-angiogenic
    substances envisaged in this invention include Angiostatin, Endostatin,
    platelet factor-4, TNP-470, thalidomide, interleukin-12 and
    metalloproteinase inhibitors. A preferred method of administration of the
    mixt. to treat a tumor is intra-arterial administration into an artery
     which provides the main blood supply for the tumor.
   506-26-3, .gamma.-Linolenic acid 593-38-4, Cis-Parinaric
    acid 1783-84-2, Dihomo-.gamma.-linolenic acid
    RL: BAC (Biological activity or effector, except adverse); BSU (Biological
    study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
        (polyunsatd, fatty acids for potentiating action of anti-angiogenic
```

L25 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: DOCUMENT NUMBER:

substances)

2001:462668 CAPLUS

TITLE:

Uterocalin, a lipocalin provisioning the preattachment equine conceptus: fatty acid and retinol binding properties, and structural characterization

AUTHOR(S): Suire, Sabine; Stewart, Francesca; Beauchamp, Jeremy; Kennedy, Malcolm W.

CORPORATE SOURCE: SOURCE:

Babraham Institute, Cambridge, CB2 4AT, UK Biochemical Journal (2001), 356(2), 369-376

CODEN: BIJOAK; ISSN: 0264-6021 Portland Press Ltd.

PUBLISHER: DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB The equine conceptus is surrounded by a fibrous capsule that persists until about day 20 of pregnancy, whereupon the capsule is lost, the conceptus attaches to the endometrium and placentation proceeds. Before attachment, the endometrium secretes in abundance a protein of the lipocalin family, uterocalin. The cessation of secretion coincides with the end of the period during which the conceptus is enclosed in its capsule, suggesting that uterocalin is essential for the support of the embryo before direct contact between maternal and fetal tissues is established. Using recombinant protein and fluorescence-based assays, we show that equine uterocalin binds the fluorescent fatty acids 11-(dansylamino)undecanoic acid, dansyl-D, L-.alpha.-amino-octanoic acid and cis-parinaric acid, and, by competition, oleic, palmitic, arachidonic, docosahexaenoic, .gamma.-linolenic, cis-eicosapentaenoic and linoleic acids. Uterocalin also binds all-trans-retinol, the binding site for which is coincident or interactive with that for fatty acids. Mol. modeling and intrinsic fluorescence anal. of the wild-type protein and a Trp .fwdarw. Glu mutant protein indicated that uterocalin has an unusually solvent-exposed Trp side chain projecting from its large helix directly into solvent. This feature is unusual among lipocalins and might relate to binding to, and uptake by, the trophoblast. Uterocalin therefore has the localization and binding activities for the provisioning of the equine conceptus with lipids including those essential for morphogenesis and pattern formation. The possession of a fibrous capsule surrounding the conceptus might be an ancestral condition in mammals; homologs of uterocalin might be essential for early development in marsupials and in eutherians in which there is a prolonged preimplantation period. 506-26-3, .gamma.-Linolenic acid 593-38-4, cis-Parinaric

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process) (fatty acid and retinol binding properties, and structural characterization of uterocalin, a lipocalin provisioning the preattachment equine conceptus)

506-26-3 CAPLUS 6,9,12-Octadecatrienoic acid, (62,92,122) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

593-38-4 CAPLUS

9,11,13,15-Octadecatetraenoic acid, (92,11E,13E,15Z)- (9CI) (CA INDEX

Examiner Anderson 703-605-1157

L25 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued) 506-26-3 CAPLUS

6,9,12-Octadecatrienoic acid, (62,92,122) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

593-38-4 CAPLUS 9,11,13,15-Octadecatetraenoic acid, (9Z,11E,13E,15Z)- (9CI) (CA INDEX

Double bond geometry as shown.

1783-84-2 CAPLUS 8,11,14-Eicosatrienoic acid, (82,112,142)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued) Double bond geometry as shown.

REFERENCE COUNT: THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

08945667 Page 47 09/23/2002

L25 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2000:247799 CAPLUS

DOCUMENT NUMBER: 132:255962

Soft capsule of Lithospermum euchromum seed oil TITLE:

INVENTOR(S): Tong, Enguo PATENT ASSIGNEE(S): Peop. Rep. China

Faming Zhuanli Shenqing Gongkai Shuomingshu, 5 pp. SOURCE:

CODEN: CNDCKEY

DOCUMENT TYPE: Patent LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

100%.

PATENT NO. KIND DATE APPLICATION NO. DATE A 19980506 CN 1996-119487 19961017 CN 1180536 Soft capsule of Lithospermum euchromum seed oil comprises cetylic acid 4.8-5.2, stearic acid 2.1-2.6, oleic acid 11.4-12.7, vitamin E 1, linoleic acid 20-20.7, .alpha.-linolenic acid 13.7-14.1, .gamma.-linolenic acid 30-31.9, parinaric acid 12.7-13.7, eicosenoic acid 1.0-1.3, and water to

IT 506-26-3, .gamma.-Linolenic acid 18427-44-6, Parinaric

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(soft capsule of Lithospermum euchromum seed oil)

506-26-3 CAPLUS 6,9,12-Octadecatrienoic acid, (6Z,9Z,12Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

18427-44-6 CAPLUS 9,11,13,15-Octadecatetraenoic acid (7CI, 8CI, 9CI) (CA INDEX NAME)

HO2C- (CH2) 7-CH=CH-CH=CH-CH=CH-CH=CH-Et

L25 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)

Me
$$(CH_2)_4$$
 Z Z $(CH_2)_4$ CO_2H

593-38-4 CAPLUS

CN 9,11,13,15-Octadecatetraenoic acid, (92,11E,13E,152) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2002 ACS 2000:98300 CAPLUS ACCESSION NUMBER: 132:132356 DOCUMENT NUMBER: Chemically induced intracellular hyperthermia for

TITLE: therapeutic and diagnostic use INVENTOR(S):

Bachynsky, Nicholas: Roy, Woodie Texas Pharmaceuticals, Inc., USA PATENT ASSIGNEE(S): PCT Int. Appl., 149 pp. CODEN: PIXXD2

DOCUMENT TYPE: Patent English LANGUAGE:

FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

SOURCE:

APPLICATION NO. DATE KIND DATE PATENT NO. WO 1999-US16940 19990727 20000210 WO 2000006143 Al W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, A2, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG 19990727 A1 20000221 AU 9951318 AU 1999-51310 AU 750313 20020718 BZ EP 1999-935949 19990727 A1 20010516 EP 1098641 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE, SI, LT, LV, FI, RO PRIORITY APPLN. INFO.: US 1998-94286P P 19980727 WO 1999-US16940 W 19990727

Therapeutic pharmacol. agents and methods are disclosed for chem. induction of intracellular hyperthermia and/or free radicals for the diagnosis and treatment of infections, malignancy, and other medical conditions. A process and compn. are provided for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial, parasitic, fungal, and viral pathogens by chem. generating heat, and/or free radicals and/or hyperthermia-inducible immunogenic determinants by using mitochondrial uncoupling agents, esp. 2,4-dinitrophenol, and their conjugates, either alone or in combination with other drugs, hormones, cytokines and radiation.

506-26-3 593-38-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (chem. induced intracellular hyperthermia for diagnostic and

therapeutic use, and use with other agents) 506-26-3 CAPLUS

6,9,12-Octadecatrienoic acid, (62,92,122) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L25 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:576773 CAPLUS

DOCUMENT NUMBER: TITLE:

Cancer management with tamoxifen or other antiestrogen and .gamma.-linolenic acid or other unsaturated fatty acid

Horrobin, David Frederick; Bryce, Richard; Hartley, INVENTOR(5): John

Scotia Holdings PLC, UK PATENT ASSIGNEE(S): SOURCE: PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

KIND DATE PATENT NO. APPLICATION NO. DATE A1 19990910 WO 1999-GB563 19990224 WO 9944600 W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG CA 1999-2322856 19990224 CA 2322856 AA 19990910 AU 1999-26320 19990224 EP 1999-906355 19990224 A1 19990920 AU 9926320 EP 1058545 A1 20001213 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI JP 2002505279 T2 20020219 JP 2000-534202 19990224 ZA 9901619 20000120 ZA 1999-1619 19990301 Α A 19980302 PRIORITY APPLN. INFO.: GB 1998-4361 W 19990224 WO 1999-GB563 AB The invention provides tamoxifen and .gamma.-linolenic acid, giving strong

synergistic action in cancer management, and prepn. of medicaments therefor. Other disclosed antiestrogens include e.g. toremifene and 4-hydroxytamoxifen; other unsatd. fatty acid include e.g.

dihomo-.gamma.-linolenic acid and eicosapentaenoic acid. IT 506-26-3, .gamma.-Linolenic acid 1783-84-2,

Dihomo-.gamma.-linolenic acid 18427-44-6, Parinaric acid RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(tamoxifen or other antiestrogen and .gamma.-linolenic acid or other

unsatd. fatty acid for cancer management) 506-26-3 CAPLUS

6,9,12-Octadecatrienoic acid, (62,92,122) - (9CI) (CA INDEX NAME) Double bond geometry as shown.

1783-84-2 CAPLUS

8,11,14-Eicosatrienoic acid, (82,112,142) - (9CI) (CA INDEX NAME)

08945667 Page 48 09/23/2002

L25 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued) Double bond geometry as shown.

18427-44-6 CAPLUS 9,11,13,15-Octadecatetraenoic acid (7CI, 8CI, 9CI) (CA INDEX NAME)

HO2C- (CH2) 7-CH=CH-CH=CH-CH=CH-CH=CH-Et

REFERENCE COUNT:

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued) CN 9,11,13,15-Octadecatetraenoic acid (7CI, 8CI, 9CI) (CA INDEX NAME)

HO2C- (CH2) 7-CH=CH-CH=CH-CH=CH-CH=CH-Et

REFERENCE COUNT:

THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 1999:399835 CAPLUS DOCUMENT NUMBER: 131:157149

A comparative study of fatty acids in human breast TITLE: milk and breast milk substitutes in Kuwait Hayat, Lamya: Al-Sughayer, Mona: Afzal, Mohammed AUTHOR (S): Biochemistry Department, Faculty of Science, Kuwait CORPORATE SOURCE: University, Al-Safat, 13060, Kuvait

Nutrition Research (New York) (1999), 19(6), 827-841 SOURCE: CODEN: NTRSDC; ISSN: 0271-5317

Elsevier Science Inc. PUBLISHER:

DOCUMENT TYPE: Journal LANGUAGE:

English AB Specific stds. of infant formula lack detailed recommendations about fatty acids in formula prepns. except for linoleic acid [18:2(n-6)]. Many fatty acids were known to be very important in early development. Human breast milk is considered the best model for designing breast milk substitutes with ideal nutritive value. Fatty acid compn. of human milk obtained from 19 full breast feeding Kuwaiti mothers and in 22 adapted formulas (breast milk substitutes) was detd. by using capillary gas chromatog. Palmitic acid (16:0), and as a consequence, total satd. fatty acids were found to be lower in human milk than formula milk. However, total mono- and polyunsatd. fatty acids were found to be higher in human milk than in formula milk. Linoleic acid [18:2(n-6)] content in formula milk was similar to human milk, while .alpha.-linolenic acid [18:3, (n-3)] showed a higher percentage in formula milk. Evidently formula milk prepns. provide essential fatty acids for infants in adequate amts. as a results of their fat blend. Formula milk tends to contain lower percentages of cis- and trans-isomeric fatty acids compared to human milk. In contrast to human milk, most formulas lacked physiol. important long-chain polyunsatd. fatty acids (LCP).

506-26-3 1783-84-2 18427-44-6, Parinaric acid RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC

(comparative study of fatty acids in human breast milk and breast milk substitutes in Kuwait)

506-26-3 CAPLUS

6,9,12-Octadecatrienoic acid, (62,92,122)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

1783-84-2 CAPLUS

8,11,14-Eicosatrienoic acid, (8Z,11Z,14Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 18427-44-6 CAPLUS

SOURCE:

L25 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:511859 CAPLUS

DOCUMENT NUMBER: 129:241957

cis-Parinaric acid is a ligand for the human TITLE: peroxisome proliferator activated receptor .gamma.:

development of a novel spectrophotometric assay for

the discovery of PPAR.gamma. ligands Palmer, Colin N. A.; Wolf, C. Roland

AUTHOR(S): Ninewells Hospital and Medical School, Biomedical

Research Centre and ICRF Molecular Pharmacology Unit,

University of Dundee, Dundee, DD1 95Y, UK FEBS Letters (1998), 431(3), 476-480

CODEN: FEBLAL; ISSN: 0014-5793 PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Peroxisome proliferator activated receptor .gamma. (PPAR.gamma.) is the subject of intense investigation as a target for drugs against diabetes, atherosclerosis and cancer. For this reason there is considerable interest in the spectrum of compds. that bind this receptor. In this paper we have identified cis-parinaric acid (CPA) as a novel hPPAR.gamma. ligand. The binding of this fatty acid to the receptor increases its fluorescence and causes a shift in the UV spectrum. This spectral shift

is reversible by competition with other known ligands for PPAR.gamma.. This report represents the first direct demonstration of a fatty acid binding to PPAR.gamma...

593-38-4, cis-Parinaric acid

RL: ANT (Analyte); BPR (Biological process); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); PROC (Process)

(cis-parinaric acid is a ligand for human peroxisome proliferator activated receptor .gamma. from development of a novel spectrophotometric assay for discovery of PPAR.gamma. ligands)

593-38-4 CAPLUS

CN 9,11,13,15-Octadecatetraenoic acid, (92,11E,13E,152)- (9CI) (CA INDEX

Double bond geometry as shown.

506-26-3, .gamma.-Linolenic acid RL: ARG (Analytical reagent use); BPR (Biological process); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)

(cis-parinaric acid is a ligand for human peroxisome proliferator activated receptor .gamma. from development of a novel spectrophotometric assay for discovery of PPAR.gamma. ligands)

506-26-3 CAPLUS 6,9,12-Octadecatrienoic acid, (6Z,9Z,12Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

08945667 Page 49 09/23/2002

L25 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)

L25 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued) 593-38-4 CAPLUS 9,11,13,15-Octadecatetraenoic acid, (92,11E,13E,152) - (9CI) (CA INDEX

Double bond geometry as shown.

125 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2002 ACS 1998:366938 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 129:156531

Apoptotic death of pancreatic cancer cells induced by TITLE: polyunsaturated fatty acids varies with double bond number and involves an oxidative mechanism

AUTHOR (S): Hawkins, R. A.; Sangster, Kathryn; Arends, M. J. University Department of Surgery, Royal Infirmary of CORPORATE SOURCE: Edinburgh NHS Trust, Edinburgh, EH3 9YW, UK

Journal of Pathology (1998), 185(1), 61-70 SOURCE:

CODEN: JPTLAS; ISSN: 0022-3417

PUBLISHER: John Wiley & Sons Ltd.

DOCUMENT TYPE: Journal

English LANGUAGE: AB Polyunsatd. fatty acids (PUFAs), reported to be cytotoxic at micromolar concns. for cancer cells in vitro and in vivo, are currently being tested in clin. trials as anti-cancer agents. This study has shown that seven PUFAs all inhibited the growth in vitro of three pancreatic cancer cell lines and the HL-60 leukemic cell line. Five PUFAs induced cell death within 20-30 h, but two less potent PUFAs induced death between 50 and 75 h. Apoptosis was demonstrated to be the mode of cell death by light, UV fluorescence, and electron microscopy, together with studies of DNA fragmentation. In a time-course study of PUFA-treated Mia-Pa-Ca-2 cells, apoptosis accounted for an av. of 80 per cent of the loss of viability, with "secondary necrosis", a feature of late apoptosis, apparently accounting for the remainder. Correlations were found between the no. of fatty acid double bonds and the proportion of cells undergoing apoptosis induced in both Mia-Pa-Ca-2 cells (R=0.88) and HL-60 cells (R=0.85) and inversely with the micromolar concns. of PUFAs required for 50 per cent inhibition of growth (IC50) of Mia-Pa-Ca-2 cells (R=-0.73). Cell death was preceded by progressively increasing lipid peroxidn. The extent of PUFA-induced lipid peroxidn., measured as malondialdehyde (MDA), also correlated with the proportion of apoptosis induced in Mia-Pa-Ca-2 cells (R=0.69) or HL-60 cells (R=0.64), as well as with the no. of fatty acid double bonds (R=0.82). PUFA-induced apoptosis was oxidative, being blocked by both vitamin E acetate and sodium selenite, the latter in a critically time-dependent manner. The cytotoxic effects of exposure to a PUFA and to .gamma.-irradn. simultaneously with, or prior to, the addn. of PUFA produced a significantly greater cell kill than either agent alone. 506-26-3, .gamma.-Linolenic acid 593-38-4, cis-Parinaric

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(apoptotic death of pancreatic cancer cells induced by polyunsatd. fatty acids varies with double bond no. and involves oxidative mechanism in relation to enhancement by .gamma.-irradn.)

6,9,12-Octadecatrienoic acid, (62,92,122) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

506-26-3 CAPLUS

L25 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:26284 CAPLUS

DOCUMENT NUMBER: 126:47036

Preparation of 1,3-propanediol derivatives for TITLE: transport of bioactive compounds

Horrobin, David Frederick; Manku, Mehar; Mcmordie, INVENTOR(S): Austin; Knowles, Philip; Redden, Peter; Pitt, Andrea;

Bradley, Paul; Wakefield, Paul Scotia Holdings Plc, UK; Horrobin, David Frederick; PATENT ASSIGNEE(S):

Manku, Mehar; Mcmordie, Austin; Knowles, Philip;

Redden, Peter; Pitt, Andrea; Bradley, Paul; Wakefield, Paul

PCT Int. Appl., 78 pp.

SOURCE: CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3 PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE ----------WO 1996-GB1053 19960501 WO 9634846 A1 19961107 W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG 19960820 ZA 9603360 19960426 ZA 1996-3360 Α 19960807 ZA 9603397 ZA 1996-3397 19960429 A ZA 9603433 19960807 ZA 1996-3433 19960430 Α CA 2218699 CA 1996-2218699 19960501 AΑ 19961107 CA 1996-2218702 19960501 CA 2218702 AΑ 19961107 AU 9655080 A1 19961121 AU 1996-55080 19960501 AU 707600 ВZ 19990715 EP 823889 19980218 EP 1996-912139 19960501 A1 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI CN 1187813 19980715 CN 1996-194780 Α 19960501 19980729 CN 1189148 CN 1996-195062 19960501 Α BR 1996-6607 BR 9606607 19981215 19960501 JP 11504914 T2 19990511 JP 1996-533121 19960501 NO 9705036 NO 1997-5036 Α 19971217 19971031 PRIORITY APPLN. INFO.: GB 1995-8823 A 19950501 GB 1995-17107 A 19950821 GB 1996-5440 A 19960315 W 19960501 WO 1996-GB1053

The prepn. of 1,3-propanediol derivs., R1OCH2CH2CH2OR2 (R1 is an acyl or fatty alc. group derived from a Cl2-30 preferably a Cl6-30 fatty acid desirably with two or more cis or trans double bonds, and R2 is hydrogen, or an acyl or fatty alc. group the same as or different, from R1 or any other nutrient, drug or other bioactive residue) for use in therapy are described. Title compds. are prepd. via acylation of 1,3-propanediol with a fatty acid followed by reaction with a bioactive compd. Title compds. are capable of crossing lipid membranes as in the skin and blood-brain barrier.

506-26-3, .gamma.-Linolenic acid 18427-44-6, Parinaric

RL: RCT (Reactant): RACT (Reactant or reagent)

08945667 Page 50 09/23/2002

L25 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued) (prepn. of 1,3-propanediol derivs. for transport of bioactive compds.) 506-26-3 CAPLUS

6,9,12-Octadecatrienoic acid, (62,92,122) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

18427-44-6 CAPLUS

9,11,13,15-Octadecatetraenoic acid (7CI, 8CI, 9CI) (CA INDEX NAME)

HO2C- (CH2) 7-CH=CH-CH=CH-CH=CH-CH=Et

L25 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)

Double bond geometry as shown.

Double bond geometry as shown.

RN 1783-84-2 CAPLUS 8,11,14-Eicosatrienoic acid, (82,112,142) - (9CI) (CA INDEX NAME)

L25 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 1996:740363 CAPLUS DOCUMENT NUMBER: 126:11535 Fatty acid salts of N-methylglucamine TITLE:

Horrobin, David Frederick: Knowles, Philip: Manku, INVENTOR(S): Mehar: Bonnett, Raymond: Stewart, John Charles

Marshall

Scotia Holdings PLC, UK PATENT ASSIGNEE(S): PCT Int. Appl., 14 pp. SOURCE:

CODEN: PIXXD2 DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO. APPLICATION NO. DATE KIND DATE WO 1996-GB952 19960419 WO 9633155 A1 19961024 W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG 19960418 19960830 ZA 1996-3103 ZA 9603103 CA 1996-2218636 19960419 CA 2218636 19961024 AA AU 9653425 AU 1996-53425 19960419 19961107 A1 20000302 AU 716680 **B2** BR 9606609 19971118 BR 1996-6609 19960419 λ EP 1996-910125 19960419 EP 821663 19980204 A1 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI JP 1996-531568 19960419 JP 11503747 T2 19990330 US 1998-930701 19980317 US 5990164 19991123 A 19950420 GB 1995-8023 PRIORITY APPLN. INFO.: WO 1996-GB952 19960419 N-methylglucamine salts of polyunsatd, essential fatty acids having 16 to 26 carbon atoms and up to six double bonds, the double bonds being in the cis or trans configuration, and their derivs. were prepd. to provide

water-sol, derivs, with improved formulation properties. Thus, N-methylglucamine was treated with docosahexaenoic acid to give the salt.

506-26-3, .gamma.-Linolenic acid 593-38-4, .alpha.-Parinaric acid 1783-84-2, Dihomo-.gamma.-linolenic acid

RL: RCT (Reactant); RACT (Reactant or reagent) (prepn. of N-methylglucamine salts of unsatd. fatty acids) 506-26-3 CAPLUS

6,9,12-Octadecatrienoic acid, (62,92,122) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

593-38-4 CAPLUS

9,11,13,15-Octadecatetraenoic acid, (92,11E,13E,152)- (9CI) (CA INDEX

L25 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2002 ACS

1995:69426 CAPLUS ACCESSION NUMBER:

122:127257 DOCUMENT NUMBER:

TITLE: The activation of porcine pancreatic lipase by cis-unsaturated fatty acids

van Kuiken, Barbara A.; Behnke, W. David AUTHOR(S):

Department of Molecular Genetics, Biochemistry and CORPORATE SOURCE: Microbiology, University of Cincinnati College of Medicine, 3110 Medical Sciences Bldg.

Ave. (ML 524), Cincinnati, OH, 45267, USA SOURCE: Biochimica et Biophysica Acta (1994), 1214(2), 148-60

CODEN: BBACAQ; ISSN: 0006-3002

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In the presence of taurodeoxycholate, cis-unsatd, fatty acids increase porcine pancreatic lipase activity 15-fold at pH 7.5. This effect is saturable with a low proportion of fatty acid to substrate. The overall angle of the fatty acid, the position of its double bond and the presence of a carboxyl group were crit. factors in whether the fatty acid effectively increased lipase activity. When the substrate is emulsified by taurodeoxycholate, the pH optimum for lipase ranges from 6.2 to 7.0. In the presence of cis-unsatd, fatty acids, the overall activity of lipase increases, the pH optimum shifts, and the pH-activity curve becomes biphasic, with one optimum around pH 7.7, and the other around pH 8.8. Fluorescence studies indicate that fatty acids bind near arom. residues in lipase, particularly tryptophan. Using the fluorescent fatty acid cis-parinaric acid, it was detd. that multiple binding sites are present with Kd values of approx. 10-6 M. Far-UV CD studies indicate that in addn. to a high affinity fatty acid binding site with a Kd of approx. 10 M-6, there is also a low affinity binding site with a Kd of approx. 10 M-4. The far-UV CD data also show that cis-unsatd, fatty acids change the conformation of lipase. It is calcd. that the percentage of .alpha. helix decreases, and the amt. of .beta. sheet and .beta. turn structure increases. Because the three-dimensional crystal structure of lipase is known, a model is proposed to describe how cis-unsatd. fatty acids

increase lipase activity. IT 506-26-3, .gamma.-Linolenic acid 593-38-4, cis-Parinaric acid 18841-21-9, trans-Parinaric acid RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process) (activation of porcine pancreatic lipase by cis-unsatd. fatty acids) 506-26-3 CAPLUS

6,9,12-Octadecatrienoic acid, (6Z,9Z,12Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

593-38-4 CAPLUS

9,11,13,15-Octadecatetraenoic acid, (9Z,11E,13E,15Z)- (9CI) (CA INDEX

Double bond geometry as shown.

08945667 Page 51 09/23/2002

L25 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)

18841-21-9 CAPLUS 9,11,13,15-Octadecatetraenoic acid, (9E,11E,13E,15E) - (9CI) (CA INDEX

Double bond geometry as shown.

L25 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)

IT 2348-97-2P 7378-85-0P RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of) 2348-97-2 CAPLUS

9,11,13,15-Octadecatetraenoic acid, methyl ester, (all-E) - (9CI) (CA

INDEX NAME)

Double bond geometry as shown.

7378-85-0 CAPLUS

9,11,13,15-Octadecatetraenoic acid, methyl ester (7CI, 8CI, 9CI) (CA

INDEX NAME)

L25 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 1994:600766 CAPLUS

121:200766 DOCUMENT NUMBER:

Oxidation of octadecatrienoic acids in the red alga-TITLE: Lithothamnion corallioides: structural and

stereochemical studies of conjugated tetraene fatty

acids and bis allylic hydroxy acids

Hamberg, Mats AUTHOR(S): CORPORATE SOURCE: Dep. Physiol. Chem., Karolinska Inst., Stockholm,

5-171 77, Swed.

Journal of the Chemical Society, Perkin Transactions SOURCE: 1: Organic and Bio-Organic Chemistry (1972-1999)

(1993), (24), 3065-72

CODEN: JCPRB4: ISSN: 0300-922X

DOCUMENT TYPE: Journal LANGUAGE: English

Enzymic oxidn. of (62,92,122)-octadeca-6,9,12-trienoic acid (.gamma.-linolenic acid) (I) in a prepn. of the red alga Lithothamnion

corallioides Crouan led to the formation of (62,8E,10E,122)-octadeca-6,8,10,12-tetraenoic acid (II) and (11R,6Z,9Z,12Z)-hydroxyoctadeca-6,9,12trienoic acid (III) as the main products. (92,122,152)-Octadeca-(9,12,15)trienoic acid (.alpha.-linolenic acid) was oxidized in an analogous way to yield (9Z, 11E, 13E, 15Z) -octadeca-9, 11, 13, 15-tetraenoic acid (.alpha.-parinaric acid), (115,92,122,152)-hydroxyoctadeca-9,12,15trienoic acid, and (14R, 9Z, 12Z, 15Z) -hydroxyoctadeca-9, 12, 15-trienoic acid. Isotope studies demonstrated that enzymic conversion of the acid I into the tetraene II was accompanied by stereospecific eliminations of the pro-S and pro-R hydrogens from C-8 and C-11, resp. The bis-allylic hydroxy acid III was formed from acid I by a reaction involving stereospecific elimination of the pro-S hydrogen from C-11 and incorporation of 1 atom of oxygen from water in the C-11 hydroxy group. Although the bis-allylic hydroxy esters were chem. convertible into conjugated tetraenes by rapid acid-catalyzed dehydration, enzymic

formation of conjugated tetraenes and hydroxy acids in Lithothamnion occurred by independent pathways.

506-26-3, .gamma.-Linolenic acid RL: BIOL (Biological study)

(enzymic oxidn.)

506-26-3 CAPLUS

6,9,12-Octadecatrienoic acid, (6Z,9Z,12Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

26474-40-8P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. and dihydroxylation)

26474-40-8 CAPLUS

9,11,13,15-Octadecatetraenoic acid, methyl ester, (2,2,E,E)- (BCI, 9CI) (CA INDEX NAME)

Double bond geometry as shown.

L25 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1994:587306 CAPLUS

DOCUMENT NUMBER:

Cholesteryl esters of unsaturated fatty acids for use TITLE: in pharmaceutical and nutritional composition

INVENTOR(S): Horrobin, David Frederick PATENT ASSIGNEE(S): Scotia Holdings PLC, UK

Eur. Pat. Appl., 11 pp. SOURCE: CODEN: EPXXDW DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PA	TENT NO.		KIND	DATE		API	PLICATIO	ON NO.	DATE			
EF	606012		A1	19940713		EP	1993-31	10599	19931229			
EF	606012		Bl	19980715								
	R: AT,	BE,	CH, DE	, DK, ES,	FR,	GB, G	GR, IE,	IT, LI,	LU, MC,	NL,	PT,	SE
AT	168267		É	19980815		AT	1993-31	10599	19931229			
ES	2119871		Т3	19981016		ES	1993-31	10599	19931229			
ΑL	9352763		A1	19940714		ΑU	1993-52	2763	19931230			
AU	673555		B2	19961114								
2A	9400025		A	19940819		ZA	1994-25	5	19940104			
CA	2112824		λA	19940707		CA	1994-21	12824	19940105			
NO	9400035		Α	19940707		NO	1994-35	5	19940105			
RU	2142468		C1	19991210		RU	1994-63	ļ	19940105			
JP	06234644		A2	19940823		JP	1994-33	38	19940106			

CN 1994-100242 19940106

US 1994-178553 19940106

A 19930106 PRIORITY APPLN. INFO.: GB 1993-125 AB Cholesterol fatty acid esters, where the fatty acid is chosen from an essential fatty acid, parinaric acid, and columbinic acid may be used in therapy, esp. in the treatment of cancer and cardiovascular disease. For example, cholesteryl (z,z,z)-octadeca-6,9,12-trienoate was prepd. Formulations contg. cholesterol .gamma.-linolenic acid ester are also

described. 157904-24-0

CN 1096197

US 5604216

RL: BIOL (Biological study) (pharmaceutical and nutritional compns. contg.)

A

Α

19941214

19970218

157904-24-0 CAPLUS

Cholest-5-en-3-ol (3.beta.)-, 9,11,13,15-octadecatetraenoate (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry unknown.

08945667 Page 52 09/23/2002

L25 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B

→ (CH2) 3 `CHMe2

506-26-3


RL: RCT (Reactant); RACT (Reactant or reagent) (reaction of, with cholesterol)

506-26-3 CAPLUS

6,9,12-Octadecatrienoic acid, (6Z,9Z,12Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L25 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)



18427-44-6 CAPLUS

CN 9,11,13,15-Octadecatetraenoic acid (7CI, 8CI, 9CI) (CA INDEX NAME)

HO2C- (CH2) 7-CH=CH-CH=CH-CH=CH-CH=CH-Et

L25 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2002 ACS 1994:465570 CAPLUS ACCESSION NUMBER: DOCUMENT NUMBER: 121:65570

Pharmaceutical compositions containing fatty acids and TITLE:

Horrobin, David F.; Scott, Catherine A. INVENTOR(S):

Scotia Holdings PLC, UK PATENT ASSIGNEE (5): Eur. Pat. Appl., 9 pp. SOURCE:

CODEN: EPXXDW DOCUMENT TYPE: Patent

LANGUAGE: English FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 585058	A1	19940302	EP 1993-306570	19930819
R: AT, BE,	CH, DE	, DK, ES, I	FR, GB, GR, IE, IT, LI	, LU, MC, NL, PT, SE
AU 9344807	Al	19940303	AU 1993-44807	19930823
AU 666961	B2	19960229		
CA 2104747	AA	19940226	CA 1993-2104747	19930824
NO 9303017	A	19940228	NO 1993-3017	19930824
JP 06157305	A2	19940603	JP 1993-209487	19930824
ZA 9306232	A	19940321	ZA 1993-6232	19930825
CN 1090776	A	19940817	CN 1993-118329	19930825
PRIORITY APPLN. INFO.	. :		GB 1992-18065	19920825
			GB 1992-22655	19921028

A method of safe i.v. administration of fatty acids or salts and derivs. thereof or conjugated fatty acids, is comprised of i.v. or sub-cutaneous administration of heparin (I) in a dose of 1,000-20,000 IU, preferably 3000-10,000 IU or equiv. anticoagulant dose of I-like proteins or peptides prior to infusion of the fatty acids. This method is useful in the treatment of cancer, viral infections and other disorders, requiring maintenance of high plasma fatty acid levels. Ampules contg. a soln. of 5-500mg/mL Li .gamma.-linolenate in 0.9% saline soln. were prepd. which could be added to i.v. fluids to achieve final concn. of 5-20mg/mL to patients pretreated with I at a dose of 3000-10,000IU.

IT 506-26-3, .gamma.-Linolenic acid 1783-84-2, Dihomo-.gamma.-linolenic acid 18427-44-6, Parinaric acid

RL: BIOL (Biological study)

(pharmaceutical compn. contg., heparin for safe administration of)

6,9,12-Octadecatrienoic acid, (62,92,122)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 1783-84-2 CAPLUS

CN 8,11,14-Eicosatrienoic acid, (82,112,142) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L25 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1990:411675 CAPLUS

DOCUMENT NUMBER:

Seasonal changes of the biochemical composition of TITLE: marine particulate matter with special reference to

fatty acids and sterols AUTHOR (5): Mayzaud, P.; Chanut, J. P.; Ackman, R. G.

INRS, Rimouski, PQ, G5L 3A1, Can. CORPORATE SOURCE:

Mar. Ecol.: Prog. Ser. (1989), 56(1-2), 189-204 SOURCE: CODEN: MESEDT; ISSN: 0171-8630

DOCUMENT TYPE: Journal

LANGUAGE: English AB Seasonal changes in particulate size spectra, biochem. compn., and fatty acid and sterol content were followed from winter to fall in a small north Atlantic coastal basin. Strong seasonality, related to both spring bloom and summer biol. prodn., was recorded for most chem. and biochem. descriptors. Size spectra were generally characterized by dominance of small particles of equiv. diam. 6.35-25.4 .mu.m, except in early summer when an addnl. component of 32.0-64.0 .mu.m became important. Changes in either C:N ratio or carbohydrate:protein ratio indicated physiol. changes that could be related to nutrient limitation or senescence. The fatty acid and sterol compn. of the lipid fraction displayed major seasonal changes which reflected: (1) the seasonal heterogeneity of the taxonomic compn. of the particles; (2) the physiol, changes within each group of organism; and (3) the various periods of low prodn. or bloom decay. Spring bloom prodn. of small to medium sized particles (12.7-50.8 .mu.m) was assocd. with C16 polyunsatd. acid, 20:5.omega.3, 24-methylenecholesterol, and desmosterol. Summer prodn. of small particles (2.0-6.4 .mu.m) was assocd. with C18 polyunsatd. acids, 22:6.omega.3, nor-24-cholesterol, and isofucosterol, while the late winter-early spring period displayed close relationships between some sats. as well as monoenes (18:0, 18:1.omega.9, 20:1.omega.9, 22:1.omega.9) and cholesterol. Post-bloom decay assocd. another group of sats. and monoenes (14:0, 20:0, 22:0, 16:1.omega.9, 16:1t.DELTA.3) and .beta.-sitosterol. Overall particulate biochem. dynamics is discussed in terms of both phytoplankton metab. and trophic influence for the zooplankton consumers.

506-26-3 18841-21-9

RL: OCCU (Occurrence) (in lipids, from marine particulate matter, temporal variations of, phytoplankton metab. and compn. in relation to, in Bedford Basin, Nova Scotia, Canada)

RN 506-26-3 CAPLUS

CN 6,9,12-Octadecatrienoic acid, (6Z,9Z,12Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

RN 18841-21-9 CAPLUS

9,11,13,15-Octadecatetraenoic acid, (9E,11E,13E,15E)- (9CI) (CA INDEX

Double bond geometry as shown.

Examiner Anderson 703-605-1157

08945667 Page 53 09/23/2002

L25 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2002 ACS (Continued)

08945667 Page 54 09/23/2002

=> log y		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	92.93	217.38
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-12.39	-12.39

STN INTERNATIONAL LOGOFF AT 08:00:54 ON 23 SEP 2002

NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area NEWS 4 Apr 09 ZDB will be removed from STN NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available NEWS 9 Jun 03 New e-mail delivery for search results now available Jun 10 MEDLINE Reload NEWS 10 NEWS 11 Jun 10 PCTFULL has been reloaded NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment NEWS 13 Jul 22 USAN to be reloaded July 28, 2002; saved answer sets no longer valid NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY NEWS 15 Jul 30 NETFIRST to be removed from STN NEWS 16 Aug 08 CANCERLIT reload NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN NEWS 18 Aug 08 NTIS has been reloaded and enhanced NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded NEWS 20 The MEDLINE file segment of TOXCENTER has been reloaded NEWS 21 Aug 19 NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced NEWS 23 Sep 03 JAPIO has been reloaded and enhanced NEWS 24 Sep 16 Experimental properties added to the REGISTRY file NEWS 25 Sep 16 Indexing added to some pre-1967 records in CA/CAPLUS NEWS 26 Sep 16 CA Section Thesaurus available in CAPLUS and CA February 1 CURRENT WINDOWS VERSION IS V6.0d, NEWS EXPRESS CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002 NEWS HOURS STN Operating Hours Plus Help Desk Availability NEWS INTER General Internet Information Welcome Banner and News Items NEWS LOGIN

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

CAS World Wide Web Site (general information)

Direct Dial and Telecommunication Network Access to STN

NEWS PHONE

NEWS WWW

FILE 'HOME' ENTERED AT 10:04:26 ON 23 SEP 2002

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST

0.21 0.21

FILE 'REGISTRY' ENTERED AT 10:04:33 ON 23 SEP 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 SEP 2002 HIGHEST RN 453593-49-2 DICTIONARY FILE UPDATES: 20 SEP 2002 HIGHEST RN 453593-49-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details: http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>

Uploading 08945667c.str

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

Ll STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 10:04:52 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 222 TO ITERATE

100.0% PROCESSED 222 ITERATIONS 2 ANSWERS

SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

Examiner Anderson 703-605-1157

08945667 Page 3 09/23/2002

BATCH **COMPLETE**

3547 TO 5333 PROJECTED ITERATIONS: 2 TO 124 PROJECTED ANSWERS:

L2 2 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 10:04:56 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 4226 TO ITERATE

100.0% PROCESSED 4226 ITERATIONS 52 ANSWERS

SEARCH TIME: 00.00.04

L3 52 SEA SSS FUL L1

=>

Uploading 08945667b.str

L4 STRUCTURE UPLOADED

=> d

L4 HAS NO ANSWERS

L4STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 14

SAMPLE SEARCH INITIATED 10:06:28 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 270 TO ITERATE

100.0% PROCESSED 270 ITERATIONS 12 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE** BATCH **COMPLETE**

PROJECTED ITERATIONS: 4415 TO 6385

PROJECTED ANSWERS: 33 TO 447

L5 12 SEA SSS SAM L4

=> s 14 full

FULL SEARCH INITIATED 10:06:32 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 5273 TO ITERATE

100.0% PROCESSED 5273 ITERATIONS 170 ANSWERS

SEARCH TIME: 00.00.02

L6 170 SEA SSS FUL L4

=>

Uploading 08945667.str

L7 STRUCTURE UPLOADED

=> d

Examiner Anderson 703-605-1157

08945667 Page 4 09/23/2002

L7 HAS NO ANSWERS
L7 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 17 full FULL SEARCH INITIATED 10:07:08 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 4726 TO ITERATE

100.0% PROCESSED 4726 ITERATIONS SEARCH TIME: 00.00.01

162 SEA SSS FUL L7

162 ANSWERS

=> fil caplus
COST IN U.S. DOLLARS

L8

SINCE FILE TOTAL ENTRY SESSION 421.22 421.43

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 10:07:14 ON 23 SEP 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Sep 2002 VOL 137 ISS 13 FILE LAST UPDATED: 22 Sep 2002 (20020922/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s 13 L9 33 L3 => s 16 L10 147 L6 => s 18 L11 315 L8

08945667 Page 5 09/23/2002

```
=> s 19 and diester
         12340 DIESTER
         10668 DIESTERS
         19831 DIESTER
                  (DIESTER OR DIESTERS)
L12
             0 L9 AND DIESTER
=> s 19 and di ester
        389809 DI
          3697 DIS
        393362 DI
                  (DI OR DIS)
        443266 ESTER
        349309 ESTERS
        643087 ESTER
                  (ESTER OR ESTERS)
           735 DI ESTER
                  (DI (W) ESTER)
L13
           0 L9 AND DI ESTER
=> s 110 and diester
         12340 DIESTER
         10668 DIESTERS
         19831 DIESTER
                  (DIESTER OR DIESTERS)
             3 L10 AND DIESTER
L14
=> s 19 and di-ester
        389809 DI
          3697 DIS
        393362 DI
                  (DI OR DIS)
        443266 ESTER
        349309 ESTERS
        643087 ESTER
                  (ESTER OR ESTERS)
           735 DI-ESTER
                  (DI(W)ESTER)
             0 L9 AND DI-ESTER
L15
=> s 111 and diester
         12340 DIESTER
         10668 DIESTERS
         19831 DIESTER
                  (DIESTER OR DIESTERS)
L16
             2 L11 AND DIESTER
=> s lll and di-ester
        389809 DI
          3697 DIS
        393362 DI
                 (DI OR DIS)
        443266 ESTER
        349309 ESTERS
        643087 ESTER
                  (ESTER OR ESTERS)
           735 DI-ESTER
                 (DI (W) ESTER)
```

08945667 Page 6 09/23/2002

L17 0 L11 AND DI-ESTER

=> d ibib abs hitstr 116 1-2

08945667 Page 7 09/23/2002

L16 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS 1995:581721 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 123:106304

Esterification of oxysterols by human plasma TITLE: lecithin-cholesterol acyltransferase

AUTHOR(S): Szedlacsek, Stefan E.; Wasowicz, Erwin; Hulea, Stefan A.; Nishida, Hiro I.; Kummerow, Fred A.; Nishida,

The Burnsides Research Laboratory, University of

CORPORATE SOURCE: Illinois, Urbana, IL, 61801, USA Journal of Biological Chemistry (1995), 270(20),

SOURCE: 11812-19

CODEN: JBCHA3; ISSN: 0021-9258 PUBLISHER: American Society for Biochemistry and Molecular

Biology

DOCUMENT TYPE: Journal LANGUAGE: English

AB In the present study, lecithin-cholesterol acyltransferase (LCAT) catalyzed esterification of oxysterols was investigated by using discoidal bilayer particles (DBP) contg. various oxysterols, phosphatidylcholines, and apolipoprotein A-I. The esterified oxysterols were analyzed by high pressure liq. chromatog., gas chromatog., and mass spectrometry. LCAT esterified all oxysterols tested that are known to be present in human plasma. The esterification yields in almost all cases were relatively high, often as high as the yield of cholesterol esterification. When DBP prepns. contg. 27-hydroxycholesterol and various phosphatidylcholines were used for the LCAT reaction, both monoesters and diesters were produced. The mass spectrometry anal, showed that the monoester was produced by the esterification of the 3.beta.-hydroxyl group and not the 27-hydroxyl group. The diesters were apparently produced by the esterification of the 27-hydroxyl group only after the esterification of the 3.beta.-hydroxyl group. Phosphatidylcholine contg. a satd. acyl group at sn-1 position and an unsatd, acyl group at sn-2 position gave generally high esterification yield. The esterification of various oxysterols was compared by using DBP contg. dioleoyl-phosphatidylcholine and individual oxysterols. All oxysterols produced 3.beta.-oleoyi monoesters. Unlike 27-hydroxycholesterol, 25-hydroxycholesterol, 7.alpha.-hydroxycholesterol, 7.beta.-hydroxycholesterol, or cholestanetriol did not produce diesters. Various factors influencing the formation of the monoesters and diesters from 27-hydroxycholesterol were investigated. When dioleoyl-phosphatidylcholine was used as the acyl donor, prolonged dialysis of DBP prepns. and increase in the ratio of the enzyme concn. to substrate particle concn. increased the diester formation. Significant amts. of diesters were also produced by using 1-palmitoyl-2-oleoylphosphatidylcholine and other phosphatidylcholines as the acyl donors. By analyzing the conditions of monoester and diester formation, a scheme for the LCAT reaction pathway was proposed.

17608-29-0

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(esterification of oxysterols by human plasma lecithin-cholesterol acyltransferase to both mono- and di- 3-acyl esters)

17688-29-8 CAPLUS

3,5,9-Trioxa-4-phosphanonacosa-14,17,20,23-tetraen-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[[(5Z,8Z,11Z,14Z)-1-oxo-5,8,11,14-

L16 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1984:468323 CAPLUS

DOCUMENT NUMBER: TITLE:

Effects of monolayer lipid structure and composition on the lipoprotein lipase-catalyzed hydrolysis of triacylglycerol

AUTHOR(S): Demel, Rudy A.; Dings, Peter J.; Jackson, Richard L. CORPORATE SOURCE: Biochem. Lab., State Univ. Utrecht, Utrecht, Neth.

Biochim. Biophys. Acta (1984), 793(3), 399-407 CODEN: BBACAQ: ISSN: 0006-3002

DOCUMENT TYPE: Journal LANGUAGE:

English AB The effect of lipid compn. and structure on the lipoprotein lipase (I)-catalyzed hydrolysis of triacylglycerols was detd. in a monolayer system consisting of purified bovine milk I and fatty acid-free albumin. In a monolayer of dioleoylphosphatidylcholine contg. 1-6 mol% of either tri[14C]oleoylglycerol or tri[14C]palmitoylglycerol, I catalyzed the

hydrolysis of the unsatd. triacylglycerol at a higher rate than the satd. lipid and in either the presence or absence of apolipoprotein C-II (apo-C-II), the activator protein for the enzyme. E.g., with 3 molt triacylglycerol and in the presence of apo-C-II, the rate of the I-catalyzed hydrolysis of tri[14C]oleoylglycerol was 27 .mu.mol oleic acid produced/h/mg I vs. 12 .mu.mol/h/mg I for tri[14C]palmitoylglycerol. The effect of phospholipid fatty acyl chain length and unsatd./satn., polar head group and surface d. on the I-catalyzed hydrolysis of tri[14C]oleoylglycerol was detd. The rate of I hydrolysis of triacylglycerol was similar whether the phospholipid was a diester or diether lipid or the polar head group was ethanolamine or choline. In general, phospholipids with shorter and unsatd. fatty acyl chains gave higher rates of I hydrolysis of triacylglycerol than the corresponding longer and satd. lipids. However, with all of the phospholipids tested, the rate of I hydrolysis decreased with increasing surface d. I showed no activity toward triacylglycerol in a monolayer of sphingomyelin; addn. of diolecylphosphatidylcholine to the monolayer enhanced the rate of I catalysis. Cholesterol (50 mol%) in a dipalmitoylphosphatidylcholine monolayer increased the rate of the I-catalyzed hydrolysis of tri[14C]oleoyiglycerol, whereas cholesterol decreased the rate in a diolecylphosphatidylcholine monolayer. The effect of phospholipid structure and surface d. on I activity could not be accounted for by the amt. of apo-C-II which was present at the interface. Based on these findings and other reports in the literature, it is suggested that the catalytic activity of I toward tri[14C] oleylglycerol in various monolayers

is dependent on the conformation or appropriate phys. state of the triacylglycerol substrate at the lipid interface. 14994-07-1 17688-29-8

RL: BIOL (Biological study) (monolayer contg., lipoprotein lipase hydrolysis of triacylglycerols

in, monolayer structure and compn. effect on)

5,8,11,14-Eicosatetraenoic acid, 1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy }methyl]-1,2-ethanediyl ester, (52,82,112,142)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L16 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS (Continued) eicosatetraenyl]oxy]-, inner salt, 4-oxide, (7R,142,17Z,20Z,23Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

PAGE 1-B

L16 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B

17688-29-8 CAPLUS

3,5,9-Trioxa-4-phosphanonacosa-14,17,20,23-tetraen-1-aminium, 4-hydroxy-N, N, N-trimethyl-10-oxo-7-[[(52,82,112,142)-1-oxo-5,8,11,14eicosatetraenyl]oxy]-, inner salt, 4-oxide, (7R,14Z,17Z,20Z,23Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Double bond geometry as shown.

PAGE 1-B

08945667 Page 8 09/23/2002

=> d ibib abs hitstr l14 1-3

Examiner Anderson 703-605-1157

08945667 Page 9 09/23/2002

114 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2002 ACS 2001:379313 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 135:162209

Tolerance and incorporation of a high-dose

eicosapentaenoic acid diester emulsion by patients with pancreatic cancer cachexia Barber, Matthew D.; Fearon, Kenneth C. H.

AUTHOR (S): University Department of Surgery, Royal Infirmary of CORPORATE SOURCE:

Edinburgh, Edinburgh, EH3 9YW, UK Lipids (2001), 36(4), 347-351 SOURCE:

CODEN: LPDSAP; ISSN: 0024-4201

PUBLISHER: AOCS Press DOCUMENT TYPE: Journal

TITLE:

English LANGUAGE: AB Chemotherapy and radiotherapy offer little benefit to patients with advanced pancreatic cancer. Eicosapentaenoic acid (EPA) has anticancer effects both in vitro and in animal models. The dose of EPA that can be administered to cancer patients has previously been limited by the low purity of available prepns. and the tolerability of large capsules. A high-purity prepn. of EPA as a 20% oil-in-water diester emulsion allowed a small study of the tolerance, incorporation, and effects of EPA in high doses in five patients with advanced pancreatic cancer. Patients underwent assessment at baseline and every 4 wk thereafter. All patients managed to tolerate a dose providing 18 g EPA per day, with doses between 9 and 27 g daily being taken for at least a month. Dosage was limited by a sensation of fullness, cramping abdominal pain, steatorrhea, and nausea. All such symptoms were controlled by dose redn. or pancreatic enzyme supplements. No other adverse effects attributable to the trial agent were obsd. Plasma phospholipid EPA content increased from around 1% at baseline to 10% at 4 wk and 20% at 8 wk. Incorporation of EPA into red blood cell phospholipids reached levels of around 10%. The present study has shown that a novel, high-purity, EPA diester emulsion can be tolerated at a dose providing around 18 g EPA per day with side-effects being easily controlled. The acceptibility of large doses of oral EPA should allow larger controlled clin. studies into potential anticancer effects of EPA.

326798-01-0 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use): BIOL (Biological study): USES (Uses)

(tolerance and incorporation of a high-dose eicosapentaenoic acid diester emulsion by patients with pancreatic cancer cachexia)

326798-01-0 CAPLUS 5,8,11,14,17-Eicosapentaenoic acid, 1,3-propanediyl ester,

(52,5'Z,8Z,8'Z,11Z,11'Z,14Z,14'Z,17Z,17'Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L14 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2000:872177 CAPLUS

DOCUMENT NUMBER: 134:172777

The effect of fatty acids and analogues upon TITLE:

intracellular levels of doxorubicin in cells displaying P-glycoprotein mediated multidrug

resistance AUTHOR(S):

Abulrob, Abedel-Nasser Ghazi; Mason, Malcolm; Bryce, Richard: Gumbleton, Mark

Pharmaceutical Cell Biology, Welsh School of Pharmacy, CORPORATE SOURCE:

Cardiff University, Cardiff, CF10 3XF, UK SOURCE:

Journal of Drug Targeting (2000), 8(4), 247-256

CODEN: JDTAEH; ISSN: 1061-186X PUBLISHER: Harwood Academic Publishers

DOCUMENT TYPE: Journal

LANGUAGE:

English Multidrug resistance mediated by overexpression of P-glycoprotein (P-gp) is a major obstacle in the chemotherapeutic management of cancer. The objectives of the current work were to examine if fatty acids affect the intracellular transport and dynamics of doxorubicin in drug-resistant cancer cell lines, and to assess if such effects were mediated through modulation of P-qp efflux pump activity. Among the range of fatty acids tested in this study, eicosapentaenoic acid diester (EPADI) increased doxorubicin accumulation [A] to 137% and retention [R] to 212% in doxorubicin-resistant MCF-7/ADR breast carcinoma cells, and [A] to 147% and [R] to 163% in vinblastine-resistant KBV1 nasopharyngeal carcinoma cells. Consistent with EPADI-induced increases in intracellular doxorubicin concns., EPADI (10 .mu.g/mL) sensitized MCF-7/ADR cells to the cytotoxic effects of doxorubicin (1 .mu.g/mL) as assessed by MTT assay (viability < 50% of control), while EPADI itself displayed no cytotoxicity. The combination of EPADI (10 .mu.g/mL) with verapamil (1 .mu.M) resulted in a considerable increase in the {A} and {R} of the model P-gp substrate rhodamine-123 within drug-resistant cells compared to when either agent were used alone. KBV1 cells treated with combination of EPADI (10 .mu.g/mL) and verapamil (1 .mu.M) achieved 160% and 1120% greater [A] and [R] of rhodamine-123, resp., compared to untreated cells. The P-qp modulatory effects of EPADI either alone, or as part of a combination with more potent inhibitors, should be further investigated. 326798-01-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(effect of fatty acids and analogs upon intracellular levels of doxorubicin in cells displaying P-glycoprotein mediated multidrug resistance)

326798-01-0 CAPLUS

5,8,11,14,17-Eicosapentaenoic acid, 1,3-propanediyl ester, (52,5'2,82,8'2,112,11'2,142,14'2,172,17'2) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.

Examiner Anderson 703-605-1157

L14 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-B

$$-(CH_2)_3$$
 $(CH_2)_3$ \overline{z} \overline{z} \overline{z}

PAGE 1-C

Et

THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-C

PAGE 1-B

THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

08945667 Page 10 09/23/2002

L14 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2002 ACS 2000:176716 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER:

CORPORATE SOURCE:

132:288942 TITLE:

Oestrogen and essential fatty acid supplementation corrects bone loss due to ovariectomy in the female Sprague Dawley rat

AUTHOR(S):

Schlemmer, C. K.: Coetzer, H.: Claassen, N.: Kruger,

Department of Physiology, University of Pretoria,

Pretoria, 0001, S. Afr. Prostaglandins, Leukotrienes and Essential Fatty Acids SOURCE:

(1999), 61(6), 381-390

CODEN: PLEAEU: ISSN: 0952-3278 Churchill Livingstone

PUBLISHER: DOCUMENT TYPE:

Journal LANGUAGE: English

Essential fatty acid deficient animals develop osteoporosis. Eicosapentaenoic acid and gamma-linoleic acid have been reported to have pos. effects on bone metab. in both the growing male rat and the ovariectomized (OVX) female rat. These effects have been further investigated using a novel gamma-linolenic/eicosapentaenoic acid diester together with an estrogen implant in the ovariectomized, female Sprague Dawley rat. Rats were sham-operated or ovariectomized at age 11 wk. Two groups of OVX rats received an estrogen implant at ovariectomy. Animals received fatty acids, linoleic acid (control) or a diester with gamma-linolenic acid and eicosapentaenoic acid as part of a semi-synthetic diet. Bone calcium content and excretion of deoxypyridinolines as marker of bone degrdn. Were measured at 14 Wk. Estrogen, as well as diester alone, increased calcium/femur to sham levels. Estrogen plus diester potentiated the effect of estrogen on bone calcium (P < 0.05 vs. OVX). At the same time, estrogen

alone and the combination of estrogen plus diester significantly reduced (P < 0.05 vs. OVX) urinary deoxypyridinoline and hydroxyproline excretion. Again, the diester potentiated the effect of estrogen. The effects of the diester alone, together with the potentiated effects of estrogen by the essential fatty acids on

osteoporosis, are novel findings. IT 204708-21-4

BIOL (Biological study); PROC (Process); USES (Uses) (estrogen and essential fatty acid supplementation corrects bone loss due to ovariectomy in female Sprague Dawley rat)

RL: BAC (Biological activity or effector, except adverse): BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use);

204708-21-4 CAPLUS

5,8,11,14,17-Eicosapentaenoic acid, 3-[(62,92,122)-1-0x0-6,9,12octadecatrienyl]oxy]propyl ester, (52,82,112,142,172) - (9CI) (CA INDEX

Double bond geometry as shown.

L14 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2002 ACS (Continued)

PAGE 1-A

PAGE 1-B

REFERENCE COUNT:

THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS 46 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

08945667 Page 11 09/23/2002

=> log y						
COST IN U.S. DOLLARS	SINCE FILE	\mathtt{TOTAL}				
	ENTRY	SESSION				
FULL ESTIMATED COST	37.78	459.21				
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL				
	ENTRY	SESSION				
CA SUBSCRIBER PRICE -3.10						

STN INTERNATIONAL LOGOFF AT 10:09:07 ON 23 SEP 2002